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Synergy and Resistance Mechanisms in R115777 and PS-341 Models of Myeloma and 
Leukemia 
 
Robert W. Buzzeo 
 
ABSTRACT 
 
The farnesyl transferase inhibitor R115777 (Zarnestra, Tipifarnib) has been found 
to have clinical activity in diverse hematopoietic tumors. Clinical efficacy, however, does 
not correlate with Ras mutation status or inhibition of farnesyl transferase. To further 
elucidate the mechanisms by which R115777 induces apoptosis and to investigate drug 
resistance, we have identified and characterized a R115777-resistant human myeloma cell 
line. 8226/R5 cells were found to be at least 50 times more resistant to R115777 
compared with the parent cell line 8226/S. 8226/R5 cells were insensitive to a diverse 
group of antitumor agents including PS-341 (Bortezomib, Velcade). Comparison of gene 
expression profiles between resistant and sensitive cells revealed expression changes in 
several genes involved in myeloma survival and drug resistance.  
Identification and characterization of the 8226/R5 cell line helped us evaluate and 
confirm that the Akt tumor survival pathway plays an important role in Tipifarnib 
induced apoptosis and resistance in myeloma cells. Additionally, 8226/R5 cells helped to 
evaluate other molecules exhibiting synergistic cell death.  In this study, we investigated 
the activity of R115777 combined with Bortezomib in microenvironment models of 
multiple myeloma and AML. The combination proved to be synergistic in multiple 
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myeloma and AML cell lines treated in suspension culture. Even in tumor cells relatively 
resistant to Tipifarnib, combined activity was maintained. Of importance, activation of the 
endoplasmic reticulum stress response was enhanced and correlated with apoptosis and 
reversal of CAM-DR.  Our study provides the preclinical rationale for trials testing the 
Tipifarnib and Bortezomib combination in patients with multiple myeloma and AML. 
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Chapter 1 
Introduction and Background 
 
1.1 Multiple myeloma 
 
Multiple myeloma (MM) also called Kahler’s disease is a B cell malignancy in 
which no curative therapy exists. The disease was first characterized by Otto Kahler in 
the 19th century. Only 32% of individuals diagnosed with MM survive for more than 5-
years (Dominik et al. 2007). The high mortality rate coupled with a painful disease state 
makes this cancer one of the more aggressive and harmful hematologic malignancies 
(Kyle et al. 2004). 
The pathogenesis of this disease is not well understood however genes involved in 
cell cycle control (cyclin D) and apoptosis (Akt) have been implicated. DNA 
translocations involving chromosomes 13 and 14 have also been noted (Badros et al. 
2007). Malignant B-cells will over-secrete the cytokine Interleukin-6 making the bone 
marrow microenvironment more suitable for tumorgenesis. Additionally the marrow 
becomes more vascular due to the tumor cells producing a protein known as VEGF 
(Badros et al. 2007).  
Diagnosis of MM is made through the use of an ELISA evaluating the levels of 
M-Protein which is a specific protein secreted by a rapidly proliferating B cell (Dominik 
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et al. 2004). Monoclonal Gammopathies of Undetermined Significance (MGUS) is the 
hypothesized precursor to multiple myeloma. In this pre-disease state patients display a 
very low level of M-protein in the serum, however this level spikes during active disease 
(Kyle et al. 2004).  Patients with multiple myeloma typically present with bone weakness, 
hypercalcemia and renal damage all related to the destruction of the skeleton. 
Additionally, individuals may exhibit immunocompromised characteristics and anemia 
because of damage or eventual ablation of the bone marrow (Kyle et al 2004).  
Multiple myeloma is a relatively uncommon disease and thus epidemiological 
studies have shown to be difficult. About 15,000 new cases of MM have been diagnosed 
each year since 2002 (Dominik et al. 2004). The disease is most common in men and the 
elderly (> 40 yrs). It accounts for 15% of all hematopoietic malignancies or 2% of all the 
cancers in the United States. Importantly, the disease is almost 2 times more common in 
African Americans and 2 times less prevalent in those of Asian descent (Dominik et al. 
2004). Cohort studies have identified a notable link between obesity and multiple 
myeloma, however the pathophysiology of this connection remains elusive. Other linkage 
factors including tobacco and aclochol abuse are beginning to be evaluated (Dominik et 
al. 2004). 
Current therapy for MM includes stem cell transplants and chemotherapy. 
Autologous stem cell transplants have been proven to increase survival time following 
chemotherapy. Many chemotherapeutic compounds induce a state of aplastic anemia in 
which the bone barrow has been ablated. To compensate for this, autologous stem cells 
have shown to decrease the morbidity rates of anemia (Kyle et al. 2004).    
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Interestingly and probably as a result of the high mortality rate of MM, 
chemotherapeutic treatments now include drugs which target-specific proteins involved 
in the pathogenesis of MM. Clincial trials for MM are relatively quickly approved 
because of the poor prognosis of those with active disease (Kyle et al. 2004). Before 
2005, the drugs which were used for treatment included the DNA damaging drugs 
Melphalin and Doxorubicin (Badros et al. 2007). In 2005 the FDA approved the use of 
Bortezomib; a proteosome inhibitor for the treatment of MM (Badros et al. 2007). The 
proteosome is a large protein complex responsible for degrading proteins in the cell. 
Hence, the proteosome is an essential part of protein regulation. Many of these proteins 
that are degraded are used by the cell to decrease proliferation and increase apoptosis – 
two opposite hallmarks of cancer.  Laboratory studies have shown that the proteosome 
becomes hyperactive in cancer cells most especially (Palumbo et al. 2008). Thus as 
predicted proteosome inhibitors have exhibited fewer side effects in patients.  This form 
of target specific therapy is a relatively new and exciting area of research and treatment. 
Regardless, tumor cells eventually succumb to resistance to many of these drugs, and 
patients relapse (Kyle et al 2004). As such the characterization and identification of 
compounds that can prevent the disease altogether remains crucial. Many drugs that 
inhibit oxidative cellular damage and help control oncogenic proteins or prevent DNA 
damage have been investigated (Badros et al 2007) 
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1.2 Drug resistance in Multiple Myeloma 
 
Myeloma patients exhibit an initial response to chemotherapy but ultimately 
succumb to drug resistance. Unresponsiveness to a wide spectrum of anti-cancer agents is 
known as multidrug resistance (MDR) (Damiano et al. 1999).  Two subsets of drug 
resistance have been characterized. De novo drug resistance includes the mechanisms that 
increase survival and contribute to the intital resistance of the drug-naïve tumor. Aquired 
resistance occurs over a period of time while the tumor is exposed to the 
chemotherapeutic agent. Aquired resistance is frequently correlated to gene mutation(s). 
Many types of de novo resistance have been well characterized including cell adhesion 
mediated drug resistance (CAM-DR) and environmental mediated drug resistance (EM-
DR) (Li et al. 2005).  The phenomenom of CAM-DR involves the interaction between the 
tumor cells and other cells in the bone marrow microenvironment, more specifically by 
contact of integrens to the substrate fibronectin (FN). EM-DR has been identified as a 
resistance type caused by soluble factors including those produced by autocrine and 
paracrine loops of the tumor cells. Additionally, resistance caused by factors released by 
bone marrow stromal cells is included in EM-DR type resistance (Li et al. 2005). As 
such, initial survival of the tumor cells via CAM-DR and/or EM-DR is more significant 
since it is the first step for tumor cells to escape drug death and eventually obtain 
acquired drug resistance (Li et al. 2005). The adhesion of cells to FN via integrins and 
subsequent cytotoxic protection has been well characterized as a substantial contributor 
to de novo drug resistance.  
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Fibronectin is an extra-cellular matrix (ECM) glycoprotein that binds to fibrin and 
collagen and is predominantly detected at contact sites between bone marrow stromal 
cells (BMSCs) (Van der Velde-Zimmermann et al. 1996). Additionally fibronectin binds 
to class of adhesion molecules knows as integrins. 
Integrins are a superfamily of adhesion molecules and are the best characterized 
for their role in regulating cell growth, differentiation and homing to the bone marrow 
(Hazlehurst et al. 2001). Integren receptors contain both α and β subunits and more than 
25 of these subunits have been identified (Hazlehurst et al. 2001). β1 integrins and 
fibronectin have been implicated in playing an important role in apoptotic suppression 
and cell survival (Damiano et el. 1999). FN adhesion through α5β1 integrins induce 
increased expression of the antiapoptotic protein Bcl-2. This upregulation protected cells 
from serum starvation (Rozzo et al. 1997). Adhesion to fibronectin has been shown to 
protect myeloma RPMI 8226 cells from VP-16, radiation and front-line 
chemotheurpuetic drugs such as melphalan and doxorubicin (Hazlehurst et al. 2001).  
Importantly, β1 integrins have been shown to activate multiple signal transduction 
pathways including FAK, MAPK, Src family kinases, PI3 kinase and AKT (Hanks et al. 
1992, Lin et al. 1997, Meng et al. 1998, Lee et al. 2000, King et al. 1997). Many of the 
studies herein utilize FN adhesion so knowledge of their relevance to integrin signaling is 
of significant importance. 
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1.3 Farnysltransferase inhibitors and Ras proteins 
 
Prenylation or isoprenylation is the addition of hydrophobic lipids to a protein. 
The three enzymes that prenylate proteins in the cell include farnesyltransferase (FTase), 
geranylgeranyltransferase (GGTase) and Rab geranylgeranyltransfeRase (Brunner et al. 
2003).  FTase adds a 15-Carbon isoprenoid lipid (farnesyl group) to the –SH of the 
cysteine of proteins which have a CAAX motif on their COOH termini. This type of post 
translational modification is termed farnesylation and is considered a type of prenylation 
event (Maurer-Stroh et al. 2003). Farnesylated proteins include the Ras superfamily of 
small GTP-binding proteins involved in the cell cycle regulation. Farnesylation causes 
the proteins to associate with the plasma membrane due to the hydrophobic nature of the 
farnesyl group.  The Ras proteins are synthesized as cytosolic precursors that must 
associate with the cell membrane to transmit signals. Subsequently, membrane 
association can lead to heightened activation of these GTP-binding proteins. Farnesyl 
transfeRase inhibitors (FTIs) represent a novel class of cancer therapeutic drugs that are 
designed to inhibit the farnesylation of Ras protein.  
The Ras superfamily of proteins is made up of 10 family proteins including Ras, 
Rho, Rab, Rap, Arf, Ran, Rheb, Rad, Rit and Miro (Munemitsu et al. 1990). They are 
implicated in cell proliferation, cytoskeletal dynamic, membrane trafficking, vasicular 
transport, nuclear transport, mitochondrial transport and the mTOR pathway. There are 
over 30 members of the Ras subfamily involved in cell proliferation. Three of these (H-
Ras, K-Ras and N-Ras) are implicated in cancer when mutated and thus become 
7 
 
constitutively active. It has been well established that Ras mutations are not required for 
tumor cell succeptibility to FTIs (Brunner et al. 2003).  However Ras mutations, most 
especially the N-Ras proto-oncogene, are detectable in ~15% of those diagnosied with 
myelodysplasia and 25% of those with acute myelogenous leukemia (Karp et al. 2001). 
As such targeting the activation of Ras for the treatment of hematopoetic malignancies 
presents as a sound approach to treatment.  
Many FTIs have been synthesized. Some drugs are specific to FTase such as the 
drug primarily used in this study – R1125777 (Tipifarnib). However others have 
exhibited high efficacy in inhibiting GGTase as well. R115777 exhibited the highest level 
of specificity and lowest level of toxicity in pre-clinical models.  Tipifarnib was 
submitted to the FDA by Johnson & Johnson for the treatment of AML in patients aged 
65 and over however approval was rejected in June of 2005. However, Tipifarnib 
exhibited similar to lower toxicity ratings in a phase III clinical trial for the treatment of 
solid tumors (Cunningham et al. 2002, Van cutsem et al. 2002). Besides relatively low 
toxicity, FTIs have a distinct spectra of activity compared with classical 
chemotherapeutic agents.  Additionally the growth inhibition by FTIs can supplement 
cytoxic effects of other drugs in an additive or synergistic way (Brunner et al. 2003). 
Because of these reasons, Tipifarnib should be considered a role in combination therapies 
for the treatment of certain tumors. 
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Chapter 2 
Identification and Characterization of a R115777 Resistant Cell Line 
 
Chapter 2 represents the following publication: Buzzeo et al. 2005  
 
 
 
 
2.1 Introduction 
 
Multiple myeloma is a plasma cell malignancy with no known curative therapy. 
RAS mutations occur frequently in myeloma (Bezieau et al. 2002, Hallek et al. 1998) and 
have been linked at least in some studies to a poor prognosis (Corradina et al. 1994, 
Bauduer et al. 1993, Liu et al 1996). Farnesyl transfeRase inhibitors (FTI) inhibit Ras 
function by preventing its posttranslational prenylation, a modification done by the 
enzyme farnesyl transfeRase (FTase). The FTI R115777 was designed as a highly 
selective inhibitor of FTase (End et al. 2001) and has been clinically tested in several 
hematopoietic tumors. This compound has shown activity in acute myelogenous 
leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome (Karp et al. 
2001, Cortes et al, 2003, Keating et al. 2002, Kurzrock et al. 2002) 
 Preclinical studies have reported that FTIs have antitumor activity in myeloma 
cell lines and primary isolates (Beaupre et al. 2003, Le Gouill et al. 2002, Bolick et al. 
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2003). Based on these observations, a phase II clinical trial testing R115777 in patients 
with relapsed myeloma was conducted(Alsina et al. 2005). Forty-three patients with a 
median of four prior treatment regimens entered the study. R115777 was well tolerated 
and 64% of patients achieved disease stabilization. Of importance, RAS mutation and 
inhibition of farnesyl transfeRase did not correlate with clinical efficacy consistent with a 
prior observation that R115777 can induce apoptosis via a Ras-independent mechanism 
(Beaupre et al. 2004). In myeloma cells, R115777 activates multiple intrinsic 
proapoptotic cascades (Beaupre et al. 2004). However, the molecules and/or signaling 
pathways that trigger these events remain elusive. To further elucidate the mechanisms 
by which R115777 induces apoptosis and to investigate drug resistance, I have 
established and characterized a R115777-resistant human multiple myeloma cell line 
(8226/R5). This line is unlike a previously described R115777-resistant colon cancer line 
(Smith et al. 2002) for resistance is unrelated to the prenylation activity of the enzyme 
FTase. This finding correlates with our observation that 8226/R5 cells are insensitive to a 
diverse group of antitumor agents, including PS-341. In this study, I investigate and 
exclude several potential mechanisms of R115777 resistance. Using comparative gene 
expression profiling (between sensitive and resistant cells), I have identified expression 
changes in several genes implicated in myeloma survival and drug resistance. Further 
evaluation of these genes may lead to the identification of novel FTI targets or resistance 
mechanisms that are clinically relevant. 
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2.2 Materials and Methods 
 
2.2.1 Cell lines and reagents 
 
 The RMPI 8226 human myeloma cell line was obtained from the American Type 
Culture Collection (Manassas, VA). 8226/LR5 and8226/Dox40 lines were developed in 
our laboratory and have been previously described (Hazlehurst et al. 2003, Dalton et al. 
1986) Sensitive and resistant 8226 cells were grown in RPMI 1640 (Mediatech, Inc., 
Herndon, VA) supplemented with 10% fetal bovine serum (Omega Scientific, Inc., 
Tarzana, CA). The 8226/R5 cell line was established by continuous exposure of 8226 
parental cells (8226/S) to increasing concentrations of R115777 for over 6 months. The 
established 8226/R5 line is maintained in 5 µmol/L R115777. 8226/R5 cells were grown 
in R115777-free supplemented medium for 2 weeks before experimentation. R115777 
and [14C]R115777 (specific activity 1.43 GBq/mMol, 3.68 MBq/mL) were kindly 
provided by David End (Johnson and Johnson Pharmaceutical Research and 
development, LLC, Titusville, NJ). PS-341 was provided by Millennium 
Pharmaceuticals, Inc. (Cambridge, MA) and FTI277 from Said M. Sebti (Moffitt Cancer 
Center and Research Institute, Tampa, FL). Additional drugs were purchased from the 
following vendors: doxorubicin hydrochloride, melphalan, and perillic acid (Sigma 
Chemical, St. Louis, MO); staurosporine and etoposide (A.G. Scientific, San Diego, CA); 
and tunicamycin (Calbiochem, San Diego, CA).Antibodies and Western blotting 
Antibodies were purchased from the following vendors: anti–K-Ras-2B (C-19; Santa 
11 
 
Cruz Biotechnology, Inc., Santa Cruz, CA); anti-HDJ-2 (NeoMarkers, Freemont, CA); 
anti-hsp90, anti-hsp70, anti-hsp27, and anti–glyceraldehyde-3-phosphate dehydrogenase 
(Stressgen Biotechnologies, San Diego, CA); and anti–a-tubulin (BD Biosciences, San 
Diego, CA). Western blotting was done as described (Beaupre et al. 2003). For the 
majority of experiments, lysates were harvested using radioimmunoprecipitation assay 
lysis buffer [150 µMol/L NaCl, 1% NP40, 0.5% deoxycholic acid, 0.1% SDS, and 50 
µMol/L Tris (pH 8.0)]. For evaluation of hsp27, hsp70, hsp90, and glyceraldehyde-3-
phosphate dehydrogenase, lysates were harvested using Baverian lysis buffer [150 
µMol/L NaCl, 1% Triton X-100, 30 µMol/L Tris (pH 7.5), and 10% glycerin]. 
 
2.2.2 Analysis of cell growth, cell cycle arrest, and cell death 
 
 Degree of resistance was determined using the tetrazolium salt 3,4,5-
dimethylazol-2-yl-2,5-diphenyl tetrazolium bromide (MTT; Sigma) reduction assay. 
8226/S and 8226/R5 cells were plated into 96-well microtiter plates at a density of 5x104 
cells/mL in 200 µl of supplemented media. Cells were exposed to a broad range of drug 
concentrations (R115777 and PS-341) in replicates of four. After a 72-hour (R115777) or 
48-hour (PS-341) incubation period at 37°C, 50 µl of 2 mg/ml MTT was added to each 
well and cells were incubated for an additional 4 hours. Plates were centrifuged for 5 
minutes at 1,200 rpm in a Sorvall RT6000D table top centrifuge (Sorvall, Asheville, NC), 
supernatants were removed, and the water-insoluble product was dissolved in 100 µl of 
100% DMSO (Sigma). Plates were shaken for 30 seconds and absorbance read at 540 nm 
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on a Wallac Victor-2 1420 Multilabel Counter (Perkin-Elmer, Torrance, CA). The 
number of surviving cells was expressed as a percentage: absorbance of the experimental 
sample/ absorbance of the control x 100. The IC50 of the drug was calculated by linear 
regression analysis using Excel software. Flow cytometric cell cycle analysis was done 
after propidium iodide staining as previously described (Beaupre et al. 2003). The 
presented histograms represent gating on live cells only. Apoptosis and cell death were 
evaluated by flow cytometry after Annexin V-FITC and propidium iodide staining as per 
the recommendations of the manufacturer (BioVision Research Products, Mountain 
View, CA). TO-PRO-3 (Molecular Probes, Eugene, OR) was substituted for propidium 
iodide in experiments where cells were treated with doxorubicin. Cell death was 
calculated as the sum of Annexin V-FITC and propidium iodide or TO-PRO-3–positive 
cells. Specific cell death was determined by subtracting background death in untreated 
samples. Determination of P-glycoprotein expression 8226/S, 8226/Dox40, and 8226/R5 
cells were washed in PBS [0.8% NaCl, 0.02% KCl, 0.14% NA2HPO4, 0.02% KH2PO4 
(pH 7.4)] and resuspended in 200 µl of ice-cold PBS containing 0.5 µg/ml anti–
Pglycoprotein- FITC antibody (BD Biosciences) or 0.5 µg/mL isotype control antibody 
anti-dansyl IgG2b,n-FITC (BD Biosciences). Samples were incubated on ice for 1 hour in 
the dark, washed twice in PBS, and analyzed by flow cytometry.  
 
2.2.3 R115777 accumulation and efflux  
To quantitate cellular accumulation of [14C]R115777, 8226/S and 8226/R5 cells 
were washed once in PBS and 1 x 106 cells were resuspended in 1 mL supplemented 
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media containing 5 µmol/L R115777 (1:2.5 dilution of [14C]R115777 to cold R115777). 
Cells were incubated at 37°C for increasing time periods and were then washed three 
times in 10 mL ice-cold PBS. Cell pellets were resuspended in 1 mL PBS and transferred 
to scintillation vials containing 10 mL Scintisafe 30% scintillation fluid (Fisher 
Scientific, Pittsburgh, PA). Samples were analyzed on a L56500 multipurpose 
scintillation counter (Beckman Coulter, Fullerton, CA). Because drug accumulation 
occurred rapidly, cells were incubated in 5 µmol/L R115777 at decreasing dilutions 
(1:10, 1:2.5, 1:1) of [14C]R115777 for 1 hour and samples were processed and analyzed 
as described above to confirm a dose-dependent accumulation of [14C]R115777 in each 
cell line. For efflux experiments, 8226/S and 8226/R5 cells were washed once in PBS and 
1 x 106 cells were resuspended in 1 mL supplemented media containing 5 µmol/L 
R115777 (1:2.5 dilution of [14C]R115777 to cold R115777). Cells were incubated for 1 
hour at 37°C and then washed three times in 10 mL PBS and placed in R115777-free 
supplemented media for increasing time periods. Samples were then processed and 
analyzed as described above. Because efflux of R115777 also occurred rapidly, cells 
were incubated with 5 µmol/L R115777 at increasing dilutions (1:1, 1:2.5, 1:10) of 
[14C]R115777 for 1 hour and then washed and placed in R115777-free media for an 
additional hour. Samples were processed and analyzed as above to confirm a dose-
dependent efflux of [14C]R115777. Experiments with 8226/S and 8226/R5 lines were 
done in parallel. 
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2.2.4 Microarray analysis 
 
2.2.4.1 Probe arrays.  
 
 The oligonucleotide probe arrays were the Affymetrix U133A human arrays. 
These arrays consist of 22,215 probe sets, which target known and suspected genes as 
well as a number of suspected splice variants. The U133A chips detect an estimated 
15,000 well characterized human genes.  
 
2.2.4.2 Sample processing for microarray analysis.  
 
 Five micrograms of total RNA derived from 8226/S, 8226/LR5, and 8226/R5 
cells served as the mRNA source for microarray analysis. The polyadenylate RNA was 
specifically converted to cDNA and then amplified and labeled with biotin following the 
procedure initially described by Van Gelder et al. (Va Gelder et al. 2000). Hybridization 
with the biotin-labeled RNA, staining, and scanning of the chips followed the proscribed 
procedure outlined in the Affymetrix technical manual and has been previously described 
(Warrington et al. 2000). 
 Scanned output files were visually inspected for hybridization artifacts and then 
analyzed using Affymetrix Microarray Suite 5.1 software. Signal intensity was scaled to 
an average intensity of 500 before comparison analysis. The MAS 5.1 software uses a 
statistical algorithm to assess increases or decreases in mRNA abundance in a direct 
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comparison between two samples (Van Gelder et al. 2000, Warrington et al. 2000). This 
analysis is based on the behavior of 11 different oligonucleotide probes designed to 
detect the same gene. The software generates a P value for the likelihood that any 
perceived difference was due to chance. The P values for all probe sets were exported to 
a text file and all pairwise comparisons were then aligned in Excel. For the 
comprehensive analysis, P < 0.05 was identified as changed (increased or decreased) for 
each individual comparison. Two independent samples from 8226/S, 8226/LR5, and 
8226/R5 cells were collected. The samples generated from the resistant cell line were 
compared with the sensitive lines in all possible combinations. Genes were ultimately 
selected if they were identified as increased in all eight comparisons or decreased in all 
eight comparisons. 
 
2.3 Results 
 
2.3.1 8226/R5 cells are resistant to R115777-induced growth arrest and cell death. 
 
 Continuous culture of 8226/S cells with increasing concentrations of R115777 
established the 8226/R5 line. In cytotoxicity assays, 8226/R5 cells were at least 50 times 
more resistant to R115777 compared with parental 8226/S cells (Fig. 2.1A). The IC50 for 
the 8226/S line was 0.1 mol/L and that for the 8226/R5 line was 5.4 µmol/L. Cell cycle 
analysis revealed that R115777 induced G1 growth arrest in 8226/S cells and this effect 
was largely abolished in the 8226/ R5 line (Fig. 2.1B). 8226/R5 cells were also protected 
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from apoptosis at concentrations of R115777 as high as 20 µmol/L (Fig. 1C; data not 
shown). The observed resistance was stable because cells cultured in R11577-free 
conditioned media for several months continued to display the resistant phenotype. 
Relative to doxorubicin- (8226/Dox 40) and melphalan resistant (8226/LR5) isogenic 
lines, 8226/R5 cells were the most resistant to R115777 (Fig. 2.1C).  
 
2.3.2 Resistance to R115777 does not correlate with K-Ras prenylation or farnesyl 
transfeRase activity.  
 
To determine whether 8226/R5 cells were cross-resistant to other compounds that 
inhibit prenylation, cells were exposed to inhibitors of FTase and geranylgeranyl 
transfeRase I (GGTase I). Similar to our results with R115777, 8226/R5 cells were 
resistant to the specific FTase inhibitor FTI 277 (22) when compared with parental 
8226/S cells (Fig. 2.1). In addition, resistance was maintained in the presence of perillic 
acid, a compound that inhibits both FTase and GGTase I (Fig. 2.1B; ref. 23). 8226 cells 
express K-Ras and harbor a codon 12 K-RAS mutation. Similar to our prior observation 
in U266 cells (Beaupre et al. 2004), K-Ras remained prenylated in both sensitive and 
resistant cells after R115777 treatment (Fig. 2.2C). Moreover, farnesylation of HDJ-2 (a 
protein that can be farnesylated but not geranylgeranylated) was inhibited in both lines 
(Fig. 2.2D). These results indicate that R115777 resistance does not correlate with the 
prenylation status of K-Ras or HDJ-2. Furthermore, the fact that HDJ-2 farnesylation can 
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be inhibited in 8226/R5 cells implies that mutation of FTase (the drug target) is not 
responsible for the development of resistance.  
 
2.3.3 Resistance is not related to decreased accumulation of R115777.  
 
Many 8226 lines that acquire drug resistance have elevated expression of P-
glycoprotein. An example of this is the 8226/Dox 40 cell line that expresses high levels 
of membrane P-glycoprotein that participates in the doxorubicin-resistant phenotype 
(Dalton et al. 1986). As expected, 8226/Dox 40 cells were found to have a marked 
increase in surface P-glycoprotein expression when compared with parent 8226/S cells 
(Fig. 2.3A). 8226/R5 cells, however, had membrane levels that were similar to that noted 
for the 8226/S line (Fig. 2.3A). Because increased expression or activity of other 
membrane pumps may also produce a resistant phenotype, we investigated the influx and 
efflux of R115777 in both 8226/S and 8226/R5 cells. Influx of R115777 occurred rapidly 
in both lines and reached steady state within 15 minutes of incubation with radiolabeled 
R115777 (Fig. 2.3B). A dose-dependent increase in R115777 uptake was also observed 
(Fig. 2.3C) and both time- and concentration-dependent experiments revealed that 
R115777 uptake was increased in 8226/R5 cells compared with the parental line. With 
regard to R115777 efflux, intracellular R115777 decreased rapidly (within 15 minutes) in 
both sensitive and resistant cells in time-course experiments (Fig. 2.3D). Furthermore, a 
dose-dependent efflux of R115777 was noted with resistant cells retaining more R115777 
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compared with sensitive 8226/S cells (Fig. 2.3E). These results indicate that 8226/R5 
resistance is not related to decreased influx or increased efflux of R115777.  
 
 
 
 
 
 
Fig. 2.1. 8226/R5 cells are highly resistant to R115777. A, degree of resistance was determined using the 
MTT reduction assay. 8226/S and 8226/R5 cells were treated with increasing concentrations of R115777 
for 72 hours. Percentage surviving cells was calculated relative to cells treated with control media only (see 
Materials and Methods). IC50 determinations were done by linear regression analysis. B, cell cycle analysis 
after R115777 treatment. Sensitive and resistant 8226 lines were treated with increasing concentrations of 
R115777 for 24 hours. Cell cycle arrest was determined by flow cytometry after propidium iodide staining. 
Gating was on live cells only. C, evaluation of cell death after R115777 treatment. 8226/S, 8226/Dox40, 
8226/LR5, and 8226/R5 cells were treated with increasing concentrations of R115777 for 72 hours. Cell 
death was determined by flow cytometry after Annexin V-FITC and propidium iodide staining. Specific 
cell death was calculated by subtracting background death in untreated samples. The presented data is 
representative of three independent experiments.  
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2.3.4 8226/R5 cells display a multidrug-resistant phenotype and resistance is not 
associated with increased expression of heat shock proteins.  
 
In an attempt to further categorize resistance, 8226/R5 cells were exposed to 
agents that induce apoptosis with diverse mechanisms of action. Compounds that have 
been reported to promote mitochondrial dysfunction, endoplasmic reticulum stress, and 
nuclear stress were tested (Fig 2.4 A-E) Surprisingly, 8226/R5 cells were resistant to all 
evaluated agents when compared with the parent 8226/S line. The proteosome inhibitor 
PS-341 has been shown to have cytotoxic activity in several chemoresistant myeloma 
lines (Ma et al. 2003). In cytotoxicity assays, 8226/R5 cells were three times more 
resistant to PS-341 when compared with 8226/S cells with an IC50 of 41.8 and 13.2 
nmol/L, respectively (Fig. 2.5A). Unlike our findings with R115777, PS-341 induced G2-
M arrest in both sensitive and resistant cells with 8226/R5 cells being relatively protected 
(Fig. 2.5B). 8226/R5 cells were also protected from PS-341–induced apoptosis at 
concentrations as high as 20 nmol/L (Fig. 2.5C: data not shown). 8226/R5 cells 
maintained a PS-341–resistant phenotype when cultured in the absence of R11577 for 
several months, indicating stable resistance.  
 Heat shock proteins have antiapoptotic properties that can protect cells from 
stressful conditions. It has been previously reported that up-regulation of hsp70 can 
protect ovarian cancer cells from FTI-induced apoptosis (Hu et al. 2003). In addition, 
blockade of hsp27 expression has been shown to overcome PS-341 resistance in 
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Fig. 2.2. Resistance in 8226/R5 cells is not linked to prenylation. A, 8226/R5 cells are resistant to the 
FTase-specific inhibitor FTI-277. 8226/S and8226 /R5 cellswere treated with increasing concentrations of 
FTI-277 for 72 hours. Cell death was determined by flow cytometry after AnnexinV-FITC and 
propidiumiodide staining. Specific cell death was calculated by subtracting background death in untreated 
samples. B, 8226/R5 cells are resistant to perillic acid, an inhibitor of both FTase and GGTase I. Sensitive 
and resistant cells were treated with increasing concentrations of perillic acid for 72 hours. Samples were 
analyzed as in (A). C, K-Ras remains prenylated in sensitive and resistant cells after R115777 treatment. 
8226/S and8226 /R5 cells were treated with control media or 5 µmol/LR115777 for 72 hours. Cell lysates 
were harvested and evaluated by Western blotting using the indicated antibodies. D, HDJ-2 farnesylation is 
inhibited in both 8226/S and 8226/R5 cell lines. Sensitive and resistant cells were treated and analyzed as 
in (C) using the indicated antibodies. u, unprocessed form; p, processed form. (A) and (B) are 
representative of three independent experiments; (C) and (D) are representative of two independent 
experiments. 
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Fig. 2.3. Resistance is not related to decreased influx or increased efflux of R115777. A, P glycoprotein 
surface expression is not increased in 8226/R5 cells. 8226/S, 8226/Dox40, and 8226/R5 cells were stained 
with anti - P-glycoprotein (dashed line histograms) or isotype control antibody (solid line histograms) as 
described in Materials and Methods. Samples were analyzed by flow cytometry. Decreased accumulation 
and/or increased efflux of R115777 is not responsible for resistance in the 8226/R5 line (B-E). B, 8226/S 
and8226 /R5 cells were exposed to 5 µmol/LR115777 (1:2.5 dilution of [14C]R115777 to coldR115777) in 
supplemented media for increasing time periods. Cells were washed and accumulation of [14C]R115777 
was quantitated by scintillation counting (see Materials and Methods). C, 8226/S and8226 /R5 cells were 
incubated in supplemented media containing 5 µmol/LR115777 at decreasing dilutions (1:10,1:2.5,1:1) of 
[14C]R115777 for1hour. Samples were processed and analyzed as in (B) to confirm a dose-dependent 
accumulation of [14C]R115777 in each line. D, sensitive and resistant lines were treated with 5 µmol/L 
R115777 (1:2.5 dilution of [14C]R115777 to cold R115777) for 1 hour, then washed and placed in 
R115777-free supplemented media for increasing time periods. Samples were processed and analyzed as in 
(B). E, 8226/S and8226/R5 cells were treated with 5 µmol/LR115777 at increasing dilutions 
(1:1,1:2.5,1:10) of [14C]R115777 for 1 hour and then washed and placed in R115777 free media for an 
additional hour. Samples were processed and analyzed as in (B) to confirm a dose-dependent efflux of 
[14C]R115777. (A), (B), and( D) are representative of two independent experiments; (C) and (E) are 
representative of three independent experiments. 
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Fig. 2.4. 8226/R5 cells harbor a multidrug-resistant phenotype and resistance does not correlate with the 
expression of heat shock proteins. 8226/R5 cells display multidrug resistance (A-E). 8226/S and8226 /R5 
lines were treated with the indicated compounds for 48 hours (A and B) or 24 hours (C-E). Cell death was 
determined by flow cytometry after Annexin V-FITC and  propidiumiodide staining. Specific cell death 
was calculated by subtracting background death in untreated samples.  The presented data is representative 
of three independent experiments. F, resistance in 8226/R5 cells is not associated with increased expression 
of heat shock proteins. 8226/S and8226 /R5 cells were treated with control media or 5 µmol/L R115777 for 
72 hours. Cell lysates were harvested and analyzed by Western blotting using the indicated antibodies (see 
Materials and Methods).  The presented data is representative of two independent experiments.  
 
lymphoma cell lines (Chauhan et al. 2003, Chauhan et al. 2004). To determine whether 
multidrug resistance was related to overexpression of heat shock proteins, sensitive and 
resistant 8226 lines were evaluated for heat shock protein expression (Fig. 2.4F). 
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Expression levels of hsp70 and hsp90 were similar in sensitive and resistant lines and 
treatment with R115777 (drug-induced stress) had no appreciable effect. Hsp27 
expression was also not effected in 8226/S cells after R115777 treatment but was 
undetectable in the 8226/R5 line. These results indicate that resistance does not correlate 
with the expression of heat shock proteins hsp27, hsp70, and hsp90.  
 
2.3.5 Transcriptional profile of 8226/R5 cells.  
  
To identify potential targets of R115777 and/or molecules associated with R115777 
resistance, we compared gene expression profiles between sensitive and resistant variants 
of 8226 cells. Direct comparisons were made between the 8226/S and 8226/R5 cell lines. 
In an attempt to reduce the number of nonspecific gene expression changes identified, 
comparisons were also made between 8226/LR5 (which possessed an intermediate degree 
of resistance to R115777) (Fig. 2.1C) and 8226/R5 cells. This approach produced 2,064 
probe sets (representing 1,666 genes) with changes unique to the 8226/R5 line. A selected 
list of genes involved in cell survival and growth, maintenance of cell cytostructure, cell-
microenvironment contact, cholesterol biosynthesis, and protein degradation are presented 
in (Table 2.1) 
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Fig. 2.5 8226/R5 cells are resistant to PS-341. A, degree of resistance was determined by the MTT 
reduction assay. 8226/S and 8226/R5 cells were treated with increasing concentrations of PS-341 for 48 
hours. Percentage surviving cells and IC50 determinations were done as in Fig 2.1. B, analysis of cell cycle 
after PS-341 treatment. Sensitive and resistant 8226 lines were treated with increasing concentrations of 
PS-341 for 24 hours. Cell cycle arrest was determined by flow cytometry after propidium iodide staining. 
Gating was on live cells only. C, evaluation of cell death after PS-341 treatment. 8226/S and 8226/R5 cells 
were treated with increasing concentrations of PS-341 for 48 hours. Cell death was determined by flow 
cytometry after Annexin V-FITC and propidium iodide staining. Specific cell death was calculated by 
subtracting background death in untreated samples. The presented data is representative of three 
independent experiments. 
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Expression Increased Expression Decreased 
Janus Kinase 2 Interleukin-6 receptor 
Signal transducer and activator of 
transcription 1 
Insulin-like growth factor 2 receptor 
Bcl-XL Mcl-1 
Phosphoinositide-3-kinase HSP27 
FGFR activating protein 1 Retinoblastoma 1 
Fibroblast growth factor 20 Transforming growth factor 
Mavalonate kinase Tumor protein p53 
Rap 2A Farnesyl diphosphate synthetase 
Rab GGase, B-subunit Lamin A/C 
Rab 4A Ras protein activator like-1 
Ras and Rab interactor 3 Ras and Rab interactor 2 
Mitogen-activated protein Kinase 1 Rab 36 
Mitogen-activated protein kinase 9 Rho GTPase-activating protein 6 
Mitogen-activated protein kinase 14 Mitogen-activated protein kinase 
phosphatase 
Cyclin D3 Cyclin D1 
Fas apoptotic inhibitory molecule Syndecan 1 
Calmodulin 3 X-box-binding protein 1 
Calpain 2 Beta-Actin 
S100 calcium binding protein A13 and A14 Fibronectin-1 
Collagan type XXI Integrin B5 
Paxillin Integrin B7 
Integrin-4 Ubiquitin-conjugating enzymes 
Proteosome inhibitor subunit 1 A100 calcium binding protein (A11 
calgizzarin) 
 
 
Table 2.1 Gene expression changes in 8226/R5 cells 
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2.4 Discussion 
 
FTIs were designed as specific inhibitors of Ras intended to interfere with a 
crucial posttranslational processing step. Ras requires the addition of a 15-carbon farnesyl 
group to its carboxyl-terminal cysteine, which permits its localization to the plasma 
membrane (a requirement for function). This modification is done by the enzyme FTase, 
the purported target of R115777. It has been well established that alternate prenylation of 
Ras may occur in the presence of FTIs (Sebti et al. 2000). This has been most notably 
described for K-Ras but also applies to the N-Ras protein. These reports are consistent 
with our prior observation in U266 cells (N-Ras–expressing line; ref. Beaupre et al. 2004) 
and our present finding that K-Ras remains prenylated in 8226/S cells after R115777 
treatment. These results suggest a Ras-independent mechanism of cell death. This is 
further supported by the clinical observation that responses to R115777 do not correlate 
with Ras mutation status or inhibition of farnesyl transfeRase measured ex vivo (Karp et 
al. 2001)Karp et al. 2001, Kurzrock et al. 2003, Alsina et al. 2004).  
We hypothesized that the isolation of a R115777-resistant human myeloma cell 
line (8226/R5) might provide insight concerning the potential targets of R115777 or 
identify novel mechanisms of FTI resistance. R115777 resistance was not associated with 
an increase in the surface expression of P-glycoprotein nor was it associated with 
decreased influx or increased efflux of R115777. In addition, the expression of heat shock 
proteins (hsp27, hsp70, hsp90) did not correlate with the drug-resistant phenotype. We 
therefore undertook molecular profiling of sensitive and resistant 8226 lines and 
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identified expression changes in several genes implicated in cell survival and drug 
resistance. They included genes involved in cell signaling, cholesterol biosynthesis, and 
protein degradation. It remains possible that molecules associated with one of these genes 
is a major target of R115777 and/or directly participates in FTI resistance.  
Our microarray data identified increased expression of several proteins associated 
with Jak-Stat signaling, including Jak2. In primary isolates, constitutive Stat3 activation 
has been observed in the majority of patients with multiple myeloma (Catlette-Falcone et 
al. 1999, Bharti et al. 2004. Stat3 homodimers and Stat1:Stat3 heterodimers seem to be 
the predominant DNA-binding forms (Catlette-Falcone et al. 1999). It has been reported 
that inhibition of Stat3 can sensitize resistant myeloma cells to chemotherapy mediated 
apoptosis (Alas et al. 2003). These results imply that Jak-Stat signaling may contribute to 
the drug-resistant phenotype. Stat3 activity has been linked to up-regulation of Bcl-XL 
(Catlette-Falcone et al. 1999) and consistent with this, Bcl-XL expression was increased 
in 8226/R5 cells. Elevated expression of Bcl-XL has been observed in several 
hematopoietic tumors, including blast crisis chronic myelogenous leukemia and non-
Hodgkin's lymphoma (Grad et al. 2000), and one study suggested that it was an indicator 
of chemoresistance in multiple myeloma (Tu et al. 1998). We have previously reported 
that R115777 can partially overcome drug resistance in U266 cells that maintain high 
levels of stable Bcl-XL expression (Beaupre et al. 2004). These findings imply that 
R115777 resistance may only in part be regulated by increased Jak-Stat signaling or Bcl-
XL expression in 8226/R5 cells.  
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Our comparative gene expression profiling also identified other genes potentially 
involved in R115777 resistance. Phosphatidylinositol 3-kinase is a heterodimer consisting 
of p85 and p110 subunits (Otsu et al. 1991, Hiles et al. 1992). The p110 isoform is 
preferentially expressed in cells of hematopoietic origin (Chantry et al. 1997, 
Vanhaesebroeck et al. 1997) and elevated expression of the catalytic polypeptide was 
observed in the 8226/R5 line. An important downstream target of phosphatidylinositol 3-
kinase is Akt/protein kinase B, a protein that is known to play a role in myeloma survival 
and drug resistance (Hideshima et al. 2001, Tu et al. 2000,  Hsu et al. 2002). 
Interestingly, it has been reported that FTI-induced apoptosis can be prevented by a 
constitutively activated form of Akt-2 (Jiang et al. 2000). Therefore, it remains possible 
that phosphatidylinositol 3-kinase/Akt signaling also contributes to R115777 resistance 
and the multidrug-resistant phenotype. Because the p110 subunit is mainly expressed in 
hematopoietic cells, it potentially represents a novel therapeutic target particularly for 
resistant tumors of hematopoietic origin.  
Our analysis also identified increased expression of mevalonate kinase, an enzyme 
associated with cholesterol biosynthesis. Influx and efflux experiments suggest that 
R115777 is retained in 8226/R5 cells compared with the parent 8266/S line. This is 
relevant because an increase in cholesterol-rich microdomains, such as lipid rafts, have 
been associated with the development of multidrug resistance (Lavie et al. 2000). 
R115777 is a lipophilic molecule that could potentially be sequestered and 
compartmentalized in such microdomains; however, in 8226/R5 cells, R115777 
efficiently inhibits FTase. Nevertheless, it remains possible that subcompartmentalization 
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of R115777 influences its interaction with unforeseen targets. Also of importance was the 
observation that 8226/R5 cells were resistant to the proteosome inhibitor PS-341. It has 
been previously reported that increased expression of hsp27 produces a PS-341–resistant 
phenotype in multiple myeloma cells (Chauhan et al. 2003). In 8226/R5 cells, however, 
hsp27 protein expression was undetectable. Our microarray analysis revealed decreased 
expression of the 26S proteosome subunit (the target of PS-341) in 8226/R5 cells when 
compared with the parental 8226/S line. This perhaps represents a novel mechanism of 
proteosome inhibitor resistance.  
In conclusion, I have identified a myeloma cell line with resistance to both 
R115777 and PS-341. Further characterization of this line may lead to identification of 
novel drug targets or resistance mechanisms that are clinically relevant.  
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Chapter 3 
 
The Akt Pathway plays an Important Role in R115777 Induced Apoptosis and Resistance 
in Multiple Myeloma 
3.1 Introduction 
 
Multiple myeloma (MM) is a malignant B-Cell neoplasm characterized by the 
proliferation of clonal plasma cells preferentially in the bone marrow (Hallek et al. 1998, 
Ghafoor et al 2002). While chemotherapy exhibits an initial response, patients eventually 
succumb to acquired drug resistance (Bergsagel et al. 1995, Dalton et al. 1997).  Current 
research is focusing on identification of targets in the myeloma cell implicated in tumor 
cell growth, survival and drug resistance.  This research has led to the development and 
study of innovative compounds such as thalidomide, immunomodulatory drugs (IMIDs) 
and proteasome inhibitors for the treatment of MM (Weber et al. 2003, Richardson et al. 
2004, Pei et al 2004, Weber et al. 2002, Santucci et al 2003). 
Ras mutations occur frequently in myeloma as then are found in 50% of patients 
with advanced disease (Neri et al. 1989).  Furthermore, patients with mutated Ras are less 
likely to respond to chemotherapy and have a shorter median survival (Liu et al. 1996).  
Therefore, the development of compounds to inhibit Ras activity may exhibit antitumor 
activity in MM as well as other cancers.  One such family of Ras-inhibiting agents is the 
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FarnesyltransfeRase inhibitors (FTIs) (Datlon et al. 1997).  Ras prenylation is necessary 
for oncogenic activity.  Prenylation is a post-translational addition of an isoprene lipid 
moiety at the cysteine residue in a consensus sequence (CAAX box) of the COOH 
terminus (Kato et al 1992, Willumsen et al. 1984, Hancock et al 1989, Sebti et al. 2000). 
Ras is preferentially prenylated by FarnesyltransfeRase (FTase), however 
GeranylgeranyltransfeRase (GGTase) will alternatively prenylate the k-Ras isoforms 
(Sebti et al. 1997, Sebti et al 2000, Sun et al. 1998).  While early generation FTIs were 
designed as peptidomimetics of the CAAX box, current molecules are mostly non-
peptide, non-thiol containing compounds with nanomolar potency including farnesyl 
pyrophosphate analogues and non-peptide compounds derived from high throughput 
screening (Cox et al, 2001).  Tipifarnib, also known as FTI-R115777 or Zarnestra is a 
non-peptidomimmetic substituted quinoline inhibitor of the CAAX binding site of FTase 
(Hahn et al. 2001, Tamoni et al. 2001).  In vitro, Tipifarnib has shown to inhibit the 
prenylation of lamin A in MCF-7 breast cancer cells (Kellard et al. 2001), and the 
prenylation of lamin B, H-Ras, and N-Ras in colon, pancreatic, and melanoma cell lines 
(End et al. 2001). 
Tipifarnib treatment of patients with advanced myeloma  in a phase II clinical 
trial exhibited disease stabilization in 64% of patients (Alsina et al. 2004).  Of 
importance, RAS mutation status and inhibition of FTase did not correlate with clinical 
efficacy.  This is consistent with prior observations that Tipifarnib can induce apoptosis 
via Ras-independent mechanisms (Beaupre et al. 2004).  Interestingly, treatment with 
32 
 
Tipifarnib decreased levels of phosphorylated Akt (pAkt) and STAT3 in bone marrow 
from patients where these tumor survival pathways were constitutively active.   
The serine/threonine kinase Akt is an important downstream target of 
phosphatidylinositol-3-kinase (PI3K) (Cantly et al. 2002).  The PI3K/Akt signaling 
pathway is a key mediator of cell survival while interacting with pro-apoptotic proteins 
including Bad, and Caspase 9, as well as the anti-apoptotic protein IKK(Nrunet et al. 
1999, Madrid et al. 2000) 
  The phase II clinical trial demonstrated disease stabilization in 2 out of 2 patients 
where Tipifarnib inhibited Akt phosphorylation.  This suggests that either pAkt or an 
upstream kinase or modulator of pAkt may be targeted by Tipifarnib.  These findings are 
consistent with those of other groups which indicate that the efficacy of FTIs anti-
proliferative and apoptotic responses on tumor cells may be due to the drug affecting 
other proteins than Ras (Takada et al. 2004).  It has been reported that the PI3-kinase/Akt 
pathway is a critical target for FTI-induced apoptosis in ovarian and pancreatic cancer 
cell lines and in Ras-transformed rodent fibroblasts, respectively (Du et al. 1999). 
 In MM primary isolates, Akt has been found to be predominately activated and 
localized to the nucleus (Alkan et al. 200).  pAkt has show to be primarily localized to the 
nucleus following receptor activation in B lymphocytes (Tu et al. 2000).  Additionally, 
activated Akt in the nucleus has been implicated in the modulation and activity of 
regulatory proteins including the Forkhead/FOXO family of transcription factors (Brunet 
et al. 1996).  No direct correlation between Akt localization and drug resistance has yet 
been characterized.  It has however been well established that Akt activation inhibits 
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transcription of RhoB (Jiang et al. 2000) and that RhoB controls Akt nuclear/cytoplasmic 
trafficking in retinal cells (Adini et al. 2003) 
  As such, we have examined the mechanisms of the cytotoxicity of Tipifarnib in 
vitro and in vivo and its correlation with the status of Akt activation.  We  have 
demonstrated that Tipifarnib induces apoptosis in a dose dependent manner in two out of 
three MM cell lines. Using a SCID-hu model of myeloma we show that Tipifarnib was 
cytotoxic to myeloma cells in vivo. Additionally, we have correlated levels of pAkt 
expression to Tipifarnib resistance with cell lines harboring higher levels of pAkt such as 
the Tipifarnib resistant RPMI-8226 cell line (8226/R5) (Buzzeo et al. 2005).  Ectopic 
expression of constitutively active Akt in B-cells induces Tipifarnib resistance and we  
identify a correlation between nuclear localization of pAkt and drug resistance in MM 
cell lines. To this end, we can confirm that the Akt tumor survival pathway plays an 
important role in Tipifarnib induced apoptosis and resistance in myeloma cell lines. 
 
3.2 Material and Methods 
 
3.2.1 Cell culture 
 
Myeloma cell lines RPMI-8226, and U266 were obtained from ATCC (Manassas, 
VA). The murine pro-B cell, Ba/F3 was obtained from DSMZ (Braunschweig, Germany). 
MM1.S cells were generously donated by Steven T. Rosen (Northwestern University, 
Chicago, Illinois). 8226/S and 8226/R5 cells have been previously characterized (Buzzeo 
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et al. 2005) and were developed in this lab. All cell lines were maintained in RPMI 
medium (CellGro, Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum 
(FBS), 100 U/mL penicillin/streptomycin, and 100 µM L-glutamine (Gemini Bio-
Products, Calabasas, CA).  Medium for the IL-3 dependant Ba/F3 cells was 
supplemented with 10% WEHI conditioned medium.  WEHI cells were obtained from 
ATCC and grown in RPMI supplemented with 10% FBS.  Cells were grown to high 
confluency, and conditioned medium filtered through a 0.4µ filter. 8226/R5 cells were 
cultured in the presence of 5µM Tipifarnib however drug was removed two weeks prior 
to experimentation. 
 
3.2.2 Drug preparation 
 
Tipifarnib (FTI-R115777, Janssen Research Institute, Beerse, Belgium) was diluted in 
DMSO (Fisher Chemical, Pittsburg, PA) to a concentration of 5mM, sonicated 10 
minutes in a water bath sonicator (Branson 3510) and stored at -20°C. 
 
3.2.3 Proliferation assay 
 
Half-log serial dilutions of Tipifarnib, from 5x10-10 to 5x10-6 M were plated in 
quadruplicate in 96 well plates. RPMI-8226, U266, and MM1.S cells in log phase growth 
were added at 10,000 cells per well (Ba/F3 cells at 5,000 cells/well) and incubated for 72 
hours at 37oC.  50µL of 2mg/ml 3-[4,5-Dimethyl-2-yl]-2,5 diphenyl-tetrazolium bromide 
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(MTT dye) (Sigma, St. Louis, MO) was added to each well.  Plates were incubated an 
additional 4 hours and centrifuged at 1,200 rpm. The supernatant was aspirated, the 
precipitate solubilized in 100 µL DMSO and the plates were shaken for 30 seconds with 
sample absorbances read at 450nM. IC50 values were calculated by linear regression 
analysis of the dose response curve. Data shown represents an average of 3 independent 
experiments and includes standard error.  
 
3.2.4 Apoptosis assay 
 
Myeloma cells were grown 48 hours in the presence of vehicle control (DMSO), 
or varying concentrations of Tipifarnib.  Cells were collected, washed in PBS, and 
stained with 5µl Annexin V-FITC (Clonetech, Palo Alto, CA) and 5µl Propidium Iodide 
(Clonetech, Palo Alto, CA) in 0.5 ml annexin binding buffer.  Apoptosis was determined 
by Flow Cytometry and analyzed using CellQuest software (Becton Dickinson, 
Carpinteria, CA).  Data shown represents an average of 3 independent experiments and 
includes standard error.  
 
3.2.5 Immunostaining 
 
For western blotting, cells were washed in PBS and lysed in Baverian lysis buffer 
(30 mM HEPES, pH 7.5, 10 mM NaCl, 1% Triton X-100, 10% glycerol, 5mM MgCl2, 1 
mM EGTA) with freshly added protease and phosphatase inhibitors (25 mM NaF, 25 
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μg/ml Leupeptin, 2mM phenylmethylsulfonylfluoride (PMSF), 2 mM sodium 
orthovanadate, 10 μg/ml soybean trypsin inhibitor, and 10 μg/ml aprotinin).  Nuclear and 
cytoplasmic fractions were separated using NE-PER (Pierce, Rockford, IL.) per the 
manufacturer’s instructions.  50 µg protein was run on 12.0% acrylamide gels and 
transferred to PVDF membranes (Millipore, Billerica, MA).  Blots were blocked in 5% 
milk in 0.1% PBS-Tween for 2 hrs, incubated overnight in primary antibody in 5% BSA, 
washed for 45 min in 0.1% Tween and incubated for 1 hr in secondary antibody.  The 
wash was repeated and bands were visualized using SuperSignal West Dura Extended 
Duration Substrate (Thermo Scientific).  Antibodies were purchased from the following 
vendors: Caspase-3, Cleaved Caspase-3 (Asp175), Akt, pAkt(Ser473), pAkt(Ser473)–
IHC Specific, HRP-anti-mouse and HRP-anti-rabbit (Cell Signaling Technologies, 
Danvers, MA); β-actin, ά-tubulin, GAPDH and anti-HA (Sigma Chemical, St. Louis, 
MO).  Data shown is representative of three independent experiments.  
For immunohistochemistry (IHC), 0.5 x 106 8226/S, 8226/R5 and MM1.S cells 
were cytospun and fixed in 4 % paraformaldehyde for 1 min, air dried and incubated in 
methanol for 5 min at -20°C.  Slides were incubated in a 1:00 dilution in Tris Bufferred 
Saline (TBS) (3%BSA) with 1:100 diluted pAkt(Ser473)-IHC Specific antibody for 1 hr, 
and washed three times in TBS (10 min/wash).  Slides were incubated with secondary at 
a dilution of 1:80 in TBS(1%BSA) for 1 hr, washed three times in TBS and incubated for 
1 hr in avidin-biotin peroxidase complex (ABC reagent). Slides were then washed three 
times in TBS and incubated with DAB reagent (15 min) (Zymed Laboratories) then 
stained with or without Hematoxylin (2 min) (Zymed Laboratories). Cells were 
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visualized by light microscopy and captures are representative of three independent 
experiments.  
 
3.2.6 Murine studies 
 
To develop myeloma SCID-hu mice, C.B-17 mice homozygous for both the 
severe combined immunodeficiency (scid) and beige (bg) mutations (C.B-1 7/GbmsTac-
Prkdcscid Lyst bg, herein referred to as SCID; Taconic, Germantown, New York) were 
used.  Human fetal bones of 18–23 weeks of gestation were obtained from Advance 
Bioscience Resource (Alameda, California) and from the General Hospital of Vienna 
(Vienna, Austria) in compliance with the regulations issued by the state and federal 
governments. SCID mice 6–8 weeks old were transplanted subcutaneously with fetal 
human bones (humerus, femur or tibia) and fetal thymus, as previously 
described(URashima et al. 1997).  Six weeks post implant 5x104 RPMI-8226 cells were 
injected directly into the implanted bones.  Beginning at 10 weeks post-implant, and each 
week thereafter, urine was collected from 12 mice and tested for free λ-light chain 
immunoglobulin levels by Radial Immunodiffusion (BIND A RID-human kappa and 
lambda free, The Binding Site Limited, Birmingham, UK).  At 12 weeks post-implant 
and after the presence of disease was established, Tipifarnib was administered by gastric 
lavage at a dose of 50 mg/kg/d, once per day for two weeks. At the conclusion of the drug 
course 10 mice were euthanized via decapitation and implanted bones were removed for 
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histology.  Wright-Gimsa staining on all 10 bone sets were performed and evaluated by 
light microscopy. 
 
3.2.7 Gene constructs, transfection and fluorescent microscopy                                                               
 
Constitutively active HA-Myr-Akt1 (Myr-Akt) was previously described (Frank 
et al. 1995), pDsRed2 (Clontech), pDsRed2-HA-Myr-Akt1 and pcDNA3 (Invitrogen) 
were generous gifts from Jin Cheng (University of South Florida, Tampa, Fl.).  Ba/F3 
cells were transfected using Nucleofection Solution-V (Amaxa Biosystems) according to 
the manufacturer’s instructions.  Cells were selected for 2 weeks in 300µg/ml G418 
(Gibco Scientific). 5,000 cells were stained with DAPI + mounting medium (Vector 
Labs, Burlingame, CA) and viewed with a fully automated, upright Zeiss Axio- 
ImagerZ.1 microscope with a 63x /1.40NA oil immersion objective, and DAPI and 
Rhodamine filter cubes.  Images were produced using the AxioCam MRm CCD camera 
and Axiovision (v.4.5). 
 
3.3 Results 
 
3.3.1 Tipifarnib induces apoptosis in RPMI-8226, and U266 myeloma cell lines, but not 
the MM1.S cell line.    
 MTT and Annexin-V binding assays were used to determine Tipifarnib sensitivity 
in three myeloma cell lines.  MTT binds active mitochondrial reductase enzymes and its 
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resulting formazin product is associated with cellular proliferation and viability.  Of the 
three cell lines examined RPMI-8226, and U266 cell lines had IC50’s less than 5 μM, the 
manufacturer’s recommended maximum dose for specific inhibition (Fig. 3.1A). RPMI-
8226 cells were most sensitive (IC50=64 nM) while U266 (IC50=2.13 μM) and MM1.S 
(IC50=12.2 μM) cells were increasingly more resistant. Notably, MM1.S cells exhibited 
an IC50 value 190 times greater than that of the RPMI-8226 cells.   
Annexin-V binding indicated that the decrease in proliferation observed in MTT 
data was due to apoptosis, not growth arrest (Fig. 3.1B). Consistent with the MTT results 
the apoptosis assay showed the RPMI-8226 cells to be most sensitive, followed by U266 
cells, with the MM1.S cells most resistant to Tipifarnib. 
Expression of effector caspase (Caspase-3) cleavage was analyzed by western 
blotting (Fig 3.2A-B).  A 48-hour time course with 1 µM Tipifarnib treating RPMI-8226 
and MM1.S cells showed induction of caspase-3 activation in RPMI-8226 cells beginning 
at 24 and continuing through 48 hours. However, the same dose failed to do so in MM1.S 
cells (Fig 3.2A). After the appropriate time time of caspase cleavage was found, a dose 
dependent increase in Caspase-3 cleavage in RPMI-8226, and U266 cell lines following 
seventy-two hour treatment with 0.05, 0.5 or 5.0 μM Tipifarnib is observed(Fig 3.2A).  A 
similar response was not observed in MM1.S cells. This data further substantiates the 
previous annexin data (Fig 3.1) that Tipifarnib is inducing apoptosis in cells sensitive to 
it, while MM1.S cells remain resistant. 
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Figure 3.1. Myeloma cell lines show variable sensitivity to Tipifarnib in vitro.  (A) Three myeloma cell 
lines were treated with log dilutions of Tipifarnib for 72 hours and viability measured by the MTT 
proliferation assay. Tipifarnib sensitivity was greatest in RPMI-8226 > U266 > MM1.S cells.  (B) These 
cell lines were also treated either with vehicle control (DMSO), 10 nM, 100 nM, or 1 μM Tipifarnib for 48 
hours.  Cells were assayed for apoptosis using Annexin V-FITC/Propidium Iodide staining as determined 
by flow cytometry.  To include early and late apoptotic events, values were derived as follows 100%-[(% 
viable of treated / % viable of DMSO ctrl /)100]. The same pattern of sensitivity as seen in the MTT assay 
can observed here. Data is presented as the avg of three independent experiments +/- SE. 
 
3.3.2 Tipifarnib is cytotoxic to myeloma cell lines as exhibited in the SCID-hu model of 
disease 
 
 To investigate the effect of Tipifarnib on MM cell lines in vivo, we used a SCID-
hu model of human myeloma previously described (URashima et al. 1997). SCID-hu 
mice had human fetal bone fragments implanted into their flanks and RPMI-8226 cells 
injected into the implant site.  Urine immunoglobulin levels (M-Spike) were used to 
detect the establishment of disease in the mice.  Mice were treated for 2 weeks with 
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Tipifarnib and sacrificed. The implanted bone tissue was removed and lymphocytes 
identified by Wright-Gimsa staining. 
 Urine λ-light chain levels in the untreated mice nearly doubled from 38.7 to 73.6 
mg/L during the four week Tipifarnib treatment (Fig 3.3A). In contRast the λ-light chain 
levels in Tipifarnib treated mice were reduced from 28.6 mg/L to undetectable levels.     
The samples from mice receiving Tipifarnib treatment had significantly fewer myeloma 
cells compared to the control samples. Femur cross sections from a control animal 
display a bone with extensive disease (Fig 3.3B). In contRast, the sections from the 
Tipifarnib treated mice exhibited myloma cells to be located on the periphery of the 
sections in close proximity to the bone marrow stroma. 
 
3.3.3 pAkt expression levels correlate with Tipifarnib cytotoxicity and drug resistance. 
 
To determine if there was a correlation between Tipifarnib sensitivity and pAkt 
levels we examined pAkt expression on Tipifarnib treated cell lines. The pAkt levels in 
the highly sensitive RPMI-8226 cell line were negligible while a dose dependent decrease 
in Akt phosphorylation was observed in U266 cells (Fig. 3.4A). In contRast, the highly 
resistant MM1.S cells consistently express high levels of pAkt and exhibit no dose 
dependent decrease in its expression.  
  To examine the relationship between Akt phosphorylation and Tipifarnib 
sensitivity in an isogenic model I utilized the Tipifarnib resistant cell line, 8226/R5.  
Western blot analysis showed a dose dependent increase in Caspase-3 cleavage in the 
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Tipifarnib sensitive parental line, but no Caspase-3 activation was observed in 8226/R5 
cells (Fig 3.4B). Furthermore, much like MM1.S cells, 8226/R5 cells express 
significantly high levels of pAkt, both at baseline levels and under the treatment of 
increasing concentrations of Tipifarnib. 
 
3.3.4 IHC reveals elevated levels of nuclear localized pAkt in Tipifarnib resistant cells. 
 
 Immunohistochemical staining can complement western blotting data when 
attempting to evaluate the cellular localization of proteins. It has been implied that the 
signal mediating AKT localization is conformation dependant or is dependent upon the 
 
 
 
Fig 3.2 Drug sensitive Myeloma cell lines undergo Tipifarnib induced apoptosis as evidenced by Caspase-3 
cleavage.  (A) Time course experiment: 2 x 106 RPMI-8226 (8226) and MM1.S cell lines were 
simultaneously harvested after treatment with 1 μM Tipifarnib for the time-points indicated.  Vehicle 
control (vc) samples were cells treated with DMSO for 48 hrs. Cell lysates were then immunoblotted for 
Procaspase and cleaved Caspase-3.  The RPMI-8226 line showed evidence of Caspase-3 activation at 24 
hours.  While no Caspase activity was observed in MM1.S cells at the time points indicated.  (b) Tipifarnib 
dose response assay: 2 x 106 RPMI-8226 (8226), U266 and MM1.S cells were treated with DMSO (vc), 10 
nM, 100 nM, or 1 μM Tipifarnib for 48 hours.  Cell lysates were then immunoblotted for Procaspase and 
cleaved Caspase-3.  A dose dependent increase in Caspase-3 cleavage can be observed in 8226 and U266 
cells however not in the highly Tipifarnib resistant MM1.S cell line. 
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Figure 3.3 Tipifarnib is cytotoxic to RPMI-8226 cells in an in vivo murine model of multiple myeloma. Six 
to eight week old SCID mice were transplanted bilaterally, in the flanks with fetal human bone. Six weeks 
post-implant, human MM cells were injected into the implanted bones. Treatment commenced when the 
presence of disease was confirmed by ELISA detection of λ-light chain protein in the urine. (A) At 12 
weeks post-implantation (week 12), before Tipifarnib treatment, both mice populations (control and 
Tipifarnib) showed significant levels of λ-light chain protein, 38.7 and 28.6 mg/L respectively in their 
urine. After 2 weeks of treatment with 50 mg/kg/d Tipifarnib (week 14), λ-light chain levels in control 
group mice nearly doubled to 73.6 mg/L while those in the Tipifarnib treated group were undetectable.  (B) 
Following post-mortem removal and subsequent Wright-Gimsa staining of the implanted bones, histology 
exhibits a marked difference between the control and drug treated groups. Cross sections of bones from 
control mice show cavities nearly full of myeloma cells in the ctrl population. In contRast the Tipifarnib 
treated group show far less disease integration with most myeloma confined to the periphery of the marrow.  
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Figure 3.4 Tipifarnib dose response assay: 2 x 106 MM cells were treated with DMSO (vc), 10 nM, 100 
nM, or 1 μM Tipifarnib for 48 hours.  Cell lysates were then immunoblotted for Akt, pAkt(Ser473) or 
cleaved Caspase-3.  (A) While endogenous Akt is expressed steadily across all three cell lines, the more 
resistant cell lines exhibit increased expression of activated Akt.  pAkt expression in RPMI-8226 cells is 
not detectable by this method, whereas it is relatively highly expressed in the MM1.S cell line. 
Furthermore, we observed a dose dependent decrease in pAkt expression in U266 cells treated with 
Tipifarnib.  (B) The RPMI-8226 Tipifarnib-resistant cell line (8226/R5) exhibits constitutive activation of 
Akt and increased endogenous levels of Akt as compared to the parental cells (8226/S).  8226/R5 cells, like 
MM1.S do not exhibit Caspase-3 activation with Tipifarnib treatment.   
 
association with other proteins (Brattain et al. 2006). Because we and others believe 
Tipifarnib may be utilizing multiple pathways to induce apoptosis, we determined it 
possible that drug resistance to Tipifarnib may be not only associated with the 
hyperexpression of AKT but also its cellular localization. In this study, MM1.S and 
8226/R5 cells expressing high levels of pAkt also exhibit a majority of the pAkt localized 
to the nucleus. This is exhibited by IHC utilizing the nuclear stain hematoxylin (Fig 3.5 
A). Activated AKT is still not readily detectable in 8226/S cells using this method. 
For further verification, nuclear and cytoplasmic extracts were prepared from 
8226/S and  8226/R5 cells and probed with anti-pAkt and anti-Akt antibodies using anti-
Poly ADP Ribose Polymerase (PARP) antibody as a control for the purity of the extracts 
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(Fig 3.5B). Even though 50µg of protein was evaluated in both nuclear and cytoplasmic 
extracts, the percentages of the target protein may be heavily increased. Thus, when 
evaluating AKT levels using a concentrated lysate such as obtained from a nuclear 
extract, pAkt is detectable in 8226/S cells, however pAkt and basal levels of AKT remain 
higher in the resistant cell line as made evident by consistent levels of the predominantly 
nuclear protein PARP between 8226/S and 8226/R5 nuclear extracts. 
 
3.3.5 Ectopic expression of constitutively active AKT promotes cytotoxic 
resistance to Tipifarnib 
 
Because of grave limitations with maintaining stable expression of exogenous 
proteins in 8226/S cells, the IL-3 dependant murine pro-B cells (Ba/F3) were used to 
ectopically express constitutively active AKT via the N-term addition of a myrostilation 
sequence which tethers Akt to the plasma membrane. Stable cell lines were created via 
selection in G418. This tethering increases its association with PI3K and 
phosphatidylinositol biphosphate rendering AKT constitutively active. Upon activation, 
AKT will release itself from the membrane and activate proteins such as MDM2, mTOR 
and NF-kB while inhibiting proteins such as BAD and FKHR. Membrane association 
exposes two crucial amino acids that are phosphorylated and necessary for activation.     
Expression was confirmed by immunoblotting with AKT, pAkt and the cloned 
HA tag.  The 30 kD shift noted between in dsRED-Myr-Akt and is accounted for by the 
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Figure 3.5 pAkt is nuclear localized in cells resistant to Tipifarnib. To perform IHC: 0.5 x 106 8226/S, 
8226/R5 and MM1.S cells were cytospun fixed in 4 % paraformaldehyde and methanol methanol then 
incubated in saline plus pAkt(Ser473)-IHC Specific antibody. Slides were then washed in TBS, incubated 
with DAB reagent and stained with or without Hematoxylin. Cells were visualized by light microscopy and 
captures are representative of three independent experiments (A). Nuclear and cytoplasmic extracts were 
prepared from 8226/S and 8226/R5 cells. 50µg of cytoplasmic or nuclear protein was run on a 12% 
acrylamide gel and proteins were probed with antibodies for basal and activated AKT. Additionally 
uncleaved PARP expression was evaluated to asses the purity of the extracts.  
 
fusion of the ~30 kD dsRED fluorescent protein (Fig 3.6 A).  Importantly however, 
Ba/F3 cells exhibit a very similar sensitivity to Tipifarnib as RPMI-8226 cells (Fig 3.6 C) 
where 8226 (IC50=114.348 nM) are only ~2.5-fold resistant to Tipifarnib compared with 
Ba/F3 cells (IC50=40.562 nM).  
Induction of Myr-Akt rendered Ba/F3 cells IL-3 independent as exhibited by 
Ba/F3(Myr-Akt) cells proliferating in the absence of IL-3. This transformed phenotype 
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has been seen with other well characterized tumor associated proteins including BCR-
ABL, JAK1, JAK2 and STAT5 (Huang et al. 2005, Onishi et al. 1998, Daley et al. 1988) 
Addition of Ba/F3(Myr-Akt) conditioned medium to Ba/F3 cells did not support 
proliferation of the non-transformed cells. This suggests that Ba/F3(Myr-Akt) cells did 
not develop an autocrine growth factor loop capable of sustaining the cells in culture in 
the absence of IL-3 (data not shown). 
 Expression of pAkt in Ba/F3 cells rendered them to be ~57 fold resistant to 
Tipifarnib as compared to cells transfected with empty vector (Fig 3.6 C). Importantly, 
this fold resistance is similar to the phenotype held by 8226/S and 8226/R5 (~48 fold 
resistance). 
Because of the presence of the Discosoma sp. red fluorescent protein in this 
construct, the localization of AKT could be evaluated and was found to be predominately 
nuclear in when stably expressed in this murine pro-B cell (Fig 3.6B). 
 
3.4 Discussion 
 
Understanding Tipifarnibs mechanism(s) of action is of significant importance.  
The drug has been shown to effectively induce apoptosis in both myeloma cell lines and 
primary isolates (Beaupre et al. 2003, Ochiai et al. 2003).  Alsina et al. showed that 64% 
of patients experienced disease stabilization in a phase II clinical trial of patients with 
advanced multiple myeloma (Alsina et al. 2004). Tipifarnib did not receive Federal Drug 
Administration approval for the treatment of acute myeloid leukemia in 2005.  Most 
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notably however the drug has exhibited extremely low toxicity in patients (Alsina et al. 
2004) while we and others have postulated that Tipifarnib like other RAS inhibitors can 
be  highly synergistic with a broad range of compounds including paclitaxel, tamoxifen 
 
 
 
Fig 3.6 Ectopic expression of constitutively active AKT promotes cytotoxic resistance to Tipifarnib. Ba/F3 
cells stably expressing pDsRed2 and pDsRed2-HA-Myr-Akt1 were lysed and probed anti-HA, anti-pAkt 
and anti-Akt antibodies to verify expression. pAkt is only detectable in those cells transfected with the 
myrostilated engineered version of AKT (A).dsRED fluorescence was evaluated using DAPI staining to 
visualize the nucleus. Ba/F3 dsRED2 Myr-Akt cells exhibited dsRED fluorescence in the nucleus of cells 
(B). The MTT cytotoxity assay was utilized to determine the IC50 of Tipifarnib against Ba/F3 cells 
overexpressing active AKT. Ba/F3 cells exhibit a very similar sensitivity to Tipifarnib as RPMI-8226 cells 
(IC50=114.348 nM) where 8226 (IC50=114.348 nM) are only ~2.5-fold resistant to Tipifarnib compared 
with Ba/F3 cells (IC50=40.562 nM).  pAkt in Ba/F3 cells rendered them to be ~57 fold resistant to 
Tipifarnib as compared to cells transfected with empty vector (C). Data shown is representative of three 
independent experiments (A), 6 images taken on three separate days (B) or the average of 3 independent 
experiments +/- Standard Error (SE). 
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and Bortezomib among others (Lebowitz et al. 2005, Yanamandra et al. 2006, Zhu et al.). 
This suggests a promising future for FTIs in combination therapy.  
 Although FTIs were designed to obstruct Ras-prenylation, mounting evidence 
indicated that FTI induced cytotoxicity involves other pathways. FTI-SCH66336, FTI-
277, and Perillic acid have all been suggested to function through non-Ras pathways 
including the NFκB, Akt2, and RhoA and Rac pathways (Takada et al. 2004, Jiang et al. 
2000, Beaupre et al. 2003).  Studies with Tipifarnib have likewise indicated that Ras-
independent mechanisms may be involved. It has been reported that Tipifarnib 
cytotoxicity in neoplastically transformed mouse cells is RhoB dependent (DuHadaway 
et al. 2003).  In human myeloma cell lines Tipifarnib has been suggested to induce 
apoptosis via other Ras-independent mechanisms, including the JAK/STAT pathway 
and/or through Bax activation of an ER stress response (Beaupre et al. 2004, Le Gouill et 
al. 2002).  
Here we report a correlation between pAkt levels and sensitivity to Tipifarnib, 
where the cell lines expressing low or minimal levels of pAkt show to be relatively more 
sensitive than those cells with high levels of pAkt.  These results are consistent with 
observations made by one group in a phase II clinical trial (Alsina et al. 2004).  A 
variance in p-Akt expression was observed between all three myeloma lines tested. 
Furthermore, the variation in pAkt expression was even more pronounced between 
standard RPMI-8226/S cells and the Tipifarnib-resistant RPMI-8226/R5 cell line. 
Additionally, it has been reported that overexpressed constitutively active myr-Akt can 
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overcome the pro-apoptotic effects of FTI (Du et al. 1999).  These findings indicate Akt 
may be an excellent target for combination drug therapy.   
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Chapter 4 
Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion–Mediated Drug 
Resistance in Multiple Myeloma and Acute Myeloid Leukemia 
 
Chapter 4 represents the following publication: Yanamandra et al. 2006 
 
4.1 Introduction 
 
It has been established in preclinical models of multiple myeloma and acute 
myeloid leukemia (AML) that the bone marrow microenvironment provides protection 
from chemotherapy- and death receptor–mediated apoptosis. This form of resistance, 
termed de novo drug resistance, occurs independent of chronic exposure to cancer-related 
therapies and likely promotes the development of multidrug resistance. Consequently, it is 
of major interest to identify compounds or drug combinations that can overcome 
environment-mediated resistance. In this study, we investigated the activity of Tipifarnib 
(Zarnestra, formerly R115777) combined with Bortezomib (Velcade, formerly PS-341) in 
microenvironment models of multiple myeloma and AML. The combination proved to be 
synergistic in multiple myeloma and AML cell lines treated in suspension culture. Even in 
tumor cells relatively resistant to Tipifarnib, combined activity was maintained. 
Tipifarnib and Bortezomib were also effective when multiple myeloma and AML cells 
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were adhered to fibronectin, providing evidence that the combination overcomes cell 
adhesion–mediated drug resistance (CAM-DR). Of importance, activation of the 
endoplasmic reticulum stress response was enhanced and correlated with apoptosis and 
reversal of CAM-DR. Multiple myeloma and AML cells cocultured with bone marrow 
stromal cells also remained sensitive, although stromal-adhered tumor cells were partially 
protected (relative to cells in suspension or fibronectin adhered). Evaluation of the 
combination using a transwell apparatus revealed that stromal cells produce a protective 
soluble factor. Investigations are under way to identify the cytokines and/or growth 
factors involved. In summary, our study provides the preclinical rationale for trials testing 
the Tipifarnib and Bortezomib combination in patients with multiple myeloma and AML.  
Multiple myeloma and acute myeloid leukemia (AML) are cancers with high 
mortality rates, where novel strategies are required to improve on current treatment 
standards. It has been well established in multiple myeloma and other malignancies that 
the interaction between tumor cells and elements of their microenvironment results in 
resistance to chemotherapy- and death receptor–mediated apoptosis (Hazlehurst et al. 
2003). This form of resistance, termed de novo drug resistance, occurs independent of 
chronic exposure to chemotherapy and likely promotes the development of multidrug 
resistance (Shain et al. 2001).  
Two basic components comprise environment-mediated drug resistance: physical 
contact between tumor cells and microenvironment components (cell adhesion mediated 
drug resistance, CAM-DR) and the local production of soluble factors. More specifically, 
in multiple myeloma and AML, it has been found that the adhesion of tumor cells (via 
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integrin receptors) to fibronectin results in a drug-resistant phenotype (Hazlehurst et al. 
2003, Matsunaga et al. 2003). Of importance, in a small series of AML patients, it was 
noted that those whose leukemic cells expressed VLA-4 ( 4ß1 integrin) had a high rate of 
relapse compared with those with low VLA-4 expression (Matsunaga et al. 2003). These 
results imply that the physical interaction between tumor cells and bone marrow 
constituents provides a refuge for minimal residual disease. Tumor-microenvironment 
contact also results in the production of soluble factors that can further accentuate the 
drug resistant phenotype (Nefedova et al. 2003). In multiple myeloma and AML, 
cytokines, such as interleukin-6 (IL-6), IL-1ß, and vascular endothelial growth factor, 
have been implicated as important growth and survival factors, and these molecules may 
also contribute to environment-mediated resistance. Based on the knowledge that the 
mechanisms of de novo drug resistance are unique and genetically distinct from those 
associated with acquired resistance (Hazlehurst et al. 2003), it is of major interest to 
identify compounds or drug combinations that are specifically active on tumor cells 
protected by the microenvironment compartment.  
The proteasome inhibitor Bortezomib (Velcade, formerly PS-341) has been found 
to have clinical activity in patients with relapsed multiple myeloma (Kane et al. 2003). 
Bortezomib is a reversible inhibitor of the 26S proteasome, a complex that plays a major 
role in protein degradation. Inhibition of this complex ultimately leads to inactivation of 
the transcription factor nuclear factor- B, a survival protein that is thought to be one of 
the drugs main targets. A previous study has reported that Bortezomib can reverse the 
CAM-DR phenotype in a multiple myeloma cell line (Mitsiades et al. Blood 2003). 
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Interestingly, we made similar observations testing the compound Tipifarnib (Zarnestra, 
formerly R115777) in multiple myeloma and AML cells.  Tipifarnib is a farnesyl 
transfeRase inhibitor (FTI) that inhibits the membrane localization of Ras resulting in a 
loss of function (End et al. 2001). Tipifarnib has been clinically tested in patients with 
multiple myeloma and AML and was found to be active in both diseases (Alsina et al. 
2004, Karp et al. 2001). In this study, we investigate the combination of Tipifarnib and 
Bortezomib in microenvironment models of multiple myeloma and AML. Our data 
provide preclinical evidence of activity for this novel drug combination.  
 
4.2 Materials and Methods 
 
4.2.1 Cell Lines 
 
RPMI 8226/S, H929, U266, KG-1, and U937 lines were obtained from the 
American Type Culture Collection (Manassas, VA). MM1s cells were kindly provided by 
Steven Rosen (Northwestern University, Chicago, IL). 8226/S, U266, U937, and MM1s 
cells were maintained in RPMI 1640 supplemented with 100 mmol/L l-glutamine 
(Mediatech, Inc., Herndon, VA) and 10% fetal bovine serum (FBS; Omega Scientific, 
Inc., Tarzana, CA). H929 cells were maintained in RPMI 1640 supplemented with 10% 
FBS and 0.05 mol/L 2-mercaptoethanol (Sigma Chemical, St. Louis, MO). The KG-1 line 
was maintained in Iscove's modification of DMEM (Mediatech) with 4 mmol/L L-
glutamine, 25 mmol/L HEPES, and 20% FBS.   HS-5 bone marrow stromal cells were 
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obtained from the American Type Culture Collection and maintained in RPMI 1640 
supplemented with 100 mmol/L L-glutamine, 10% FBS, and 1% penicillin/streptomycin. 
HS-5 green fluorescent protein (GFP) stromal cells were developed by stably expressing 
enhanced green fluorescent protein under hygromycin (Invitrogen, Carlsbad, CA) 
selection (50 µg/mL).  
 
4.2.2.Compounds 
 
Tipifarnib was kindly provided by David End (Johnson & Johnson 
Pharmaceutical Research and Development, LLC, Titusville, NJ). Tipifarnib was 
dissolved in 100% DMSO (Sigma Chemical) and sonicated for 10 minutes at room 
temperature. Bortezomib (Millennium Pharmaceuticals, Cambridge, MA) was also 
dissolved in 100% DMSO, and both compounds were stored at –20°C before use.  
 
4.2.3 Patient samples.  
 
Multiple myeloma and AML patient samples were collected under two 
Institutional Review Board–approved protocols (MCC# 13715 and MCC# 13947/13355). 
After obtaining informed consent for bone marrow aspiration, mononuclear cells were 
isolated by Ficoll-Hypaque gradient purification as per the manufacturer's instructions 
(Amersham Biosciences, Piscataway, NJ). Primary isolates were exposed to Tipifarnib 
and Bortezomib and analyzed as described below.  
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To establish patient bone marrow stromal cells, multiple myeloma patient 
specimens with <20% myeloma cells were cultured continuously in MEM-  medium 
(Invitrogen) supplemented with 15% FBS and 1% penicillin with streptomycin until an 
adherent layer of stromal cells predominated. AML patient specimens were processed by 
CD33+ selection using CD33 microbeads and the AutoMacs magnetic cell sorter 
(Miltenyi Biotec, Inc., Auburn, CA). CD33– populations were cultured continuously as 
above. For coculture experiments, stromal cells were seeded to near confluence and 
incubated overnight at 37°C. Cell lines were adhered, exposed to Tipifarnib and 
Bortezomib, and analyzed as described below.  
 
4.2.4 Combination index analysis.  
 
The dose-effect relationship between Tipifarnib and Bortezomib was analyzed 
using CalcuSyn software (Biosoft, Ferguson, MO). The combination index equation is 
based on the following multiple drug effect equation of Chou-Talalay (Chou et al. 1984): 
combination index = (D)1 / (Dx)1 + (D)2 / (Dx)2 + (D)1(D)2 / (Dx)1 / (Dx)2. Combination 
index = 1, >1, or <1 is considered additive, antagonistic, or synergistic, respectively. 
Drug combination studies were based on the fraction of cells affected relative to untreated 
controls. The mean and SD of the combination index were calculated using the Monte 
Carlo algorithm. To evaluate the relative contribution of each agent, 8226 and U937 cells 
were seeded at 1 x 103 per well and exposed to five concentrations of Tipifarnib, 
Bortezomib, and the combination (constant molar ratio, 100:1). After 72 hours at 37°C, 
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cytotoxicity was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide assay as previously described (Damiano et al. 1999). 
 
4.2.5 Fibronectin adhesion and cell death analysis.  
 
Adhesion of primary isolates and tumor cell lines to fibronectin was done as 
previously described (Damiano et al. 1999). For cell lines, adhered tumor cells were 
incubated overnight at 37°C, and then control-supplemented media or Bortezomib ± 
Tipifarnib was added for an additional 24 hours. In primary isolates, control-
supplemented media or Bortezomib ± Tipifarnib was added for 24 hours after 2 hours of 
adhesion. In parallel, primary isolates or tumor cell lines were cultured in 0.1% bovine 
serum albumin–coated plates (Boehringer-Mannheim, Indianapolis, IN; multiple 
myeloma) or 0.1% poly-hema (Sigma, St. Louis, MO)–coated plates (AML) and exposed 
to control media or Bortezomib ± Tipifarnib as above. Cell death was determined by flow 
cytometry after Annexin V/FITC (Biovision, Mountain View, CA) and propidium iodide 
(Biovision) or 7-amino actinomycin-D (BD PharMingen, San Jose, CA) staining as 
described previously (Beaupre et al. 2003). In primary isolates, samples were also stained 
with anti CD138 (BD PharMingen, San Jose, CA; myeloma cells) or anti CD33 (BD 
PharMingen; leukemic cells) antibodies to identify tumor cell populations.  
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4.2.6 Adhesion assays.  
 
Adhesion assays were done similar to previously described (Damiano et al. 1999) 
using the cell tracker 5-chloromethylfluorescein diacetate (Molecular Probes, Eugene, 
OR). For pre-adhesion drug treatment, tumor cells were incubated with Tipifarnib (5 
µmol/L), Bortezomib (5 nmol/L), or the combination for 2 hours before adhesion to 
fibronectin. After 2 hours of adhesion, wells were washed and fluorescence was measured 
at 490 nm on a Wallac Victor-2 1420 Multilabel Counter. For post-adhesion drug 
treatment, tumor cells were stained with 5-chloromethylfluorescein diacetate (as above) 
and then adhered to fibronectin for 2 hours followed by exposure to Tipifarnib (5 
µmol/L), Bortezomib (5 nmol/L), or the combination for an additional 2 hours. Wells 
were then washed, and absorbance was read as described.  
 
4.2.7 Adhesion to bone marrow stroma and cell death analysis 
 
In coculture experiments, HS-5 GFP stromal cells were seeded to near confluence 
and incubated overnight at 37°C. The next morning, stromal cells were washed once with 
serum-free medium, and primary isolates or tumor cell lines were allowed to adhere for 2 
hours in either serum-free MEM (Alpha MEM, Invitrogen) or RPMI 1640, respectively. 
Nonadhered cells were removed, and samples were then exposed to control supplemented 
media or Bortezomib ± Tipifarnib for 24 to 36 hours (see figure legends). Percent cell 
death was determined by flow cytometry as described above. For coculture experiments 
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involving cell lines, gating on GFP– populations identified tumor cells. In primary 
isolates, additional staining with anti-CD138 (myeloma cells) or anti-CD33 (leukemic 
cells) antibodies distinguished tumor cells from background mononuclear cells. For our 
experiments, we also determined the number of live cells per sample using flow 
cytometry as previously described (Beaupre et al. 2003). 
  
4.2.8 Transwell analysis 
 
8226 myeloma and U937 leukemia cells were either adhered (as described above) 
or separated from HS-5 GFP stromal cells by a Transwell insert (costar, 0.4-µm mesh, 12-
mm diameter; Corning, Corning, NY). Cells were treated with either control-
supplemented media or the Tipifarnib (5 µmol/L) and Bortezomib (5 nmol/L) 
combination for 36 hours. Cell death was determined by flow cytometry after staining 
with Annexin V/FITC and 7-amino actinomycin-D. Cell death of multiple myeloma and 
AML cells was determined in coculture by gating on GFP– populations. 
  
4.2.9 Western blotting 
 
Western blotting was done as described previously (Beaupre et al. 2003) . 
Antibodies were purchased from the following vendors: GADD153 and anti-K-Ras-2B 
(Santa Cruz Biotechnology, Santa Cruz, CA), ß-actin (Sigma Chemical), anti-HDJ-2 
(NeoMarkers, Freemont, CA). Densitometry was done by scanning radiographic images, 
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and bands were quantitated using Alpha Ease image analysis software (Alpha Innotech 
Corp., San Leandro, CA). 
 
4.2.10 Proteasome assay  
 
8226/S myeloma cells (4 x 106) were exposed to control media, Tipifarnib, 
Bortezomib, or the combination for 2 hours at 37°C. Cells were harvested, washed twice 
with ice-cold PBS, and then lysed in 50 µL of TE buffer [10 mmol/L Tris, 1 mmol/L 
EDTA (pH 7.9)]. Total protein was quantitated using a Bio-Rad protein assay kit 
(Hercules, CA), and 10 µg of protein were analyzed for proteasome activity using a 20S 
proteasome activity assay as per the manufacturer's instructions (Chemicon International, 
Temecula, CA). 
 
4.3 Results 
 
4.3.1 Tipifarnib and Bortezomib are synergistic in multiple myeloma and AML cell lines.  
 
It has previously been reported that FTIs and proteasome inhibitors induce 
apoptosis in multiple myeloma (Mitsiades et al. 2003, Beaupre et al. 2003, Le Gouill et 
al. 2002, Bolick et al. 2003, Hideshima et al. 2001) and leukemic (Beaupre et al. 1999, 
Dai et al. 2003) (cell lines. By analyzing the activity of Tipifarnib and Bortezomib as 
single agents in several representative lines, we defined concentrations with low toxicity 
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for combination studies (data not shown). We first tested Tipifarnib and Bortezomib on a 
diverse group of myeloma lines maintained in suspension culture (Fig 4.1 A-C). Evidence 
for greater than additive cell death was observed and was most pronounced in H929 and 
MM1s cells (Fig 4.1 A and C). Interestingly, the MM1s line was relatively resistant to 
single-agent Tipifarnib, yet the combination maintained its activity. We also tested KG-1 
leukemia cells and found that they were sensitive although to a lesser degree when 
compared with our myeloma lines (Fig 4.1D). To confirm that Tipifarnib and Bortezomib 
were synergistic in vitro, 8226/S myeloma cells and U937 leukemia cells were treated 
with single-agent Tipifarnib, Bortezomib, and the combination in cell suspension.  
Combination index analysis revealed synergistic activity between the two compounds at 
several dose combinations tested (Fig 4.2 A and B). These results indicate that Tipifarnib 
combined with Bortezomib is an active regimen in diverse multiple myeloma and AML 
cell lines. 
 
 4.3.2 Tipifarnib combined with Bortezomib overcomes CAM-DR.  
 
It has previously been established that adherence of multiple myeloma and AML cells to 
the extracellular matrix component fibronectin results in resistance to chemotherapeutic 
agents, including melphalan, doxorubicin, and cytosine arabinoside (Matsunaga et al. 
2003). To determine whether Tipifarnib and Bortezomib overcome CAM-DR, 8226/S 
myeloma (Fig 4.3A and B) and U937 leukemia cells (Fig 4.3 C and D) were adhered 
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Fig. 4.1 Tipifarnib combined with Bortezomib induces cell death in diverse multiple myeloma and AML 
cell lines. H929 (A), U266 (B), MM1s (C), or KG-1 (D) cell lines were treated with the indicated 
concentrations of Tipifarnib, Bortezomib, or the combination for 24 hours in cell suspension. Cell death 
was determined by flow cytometry after Annexin V/FITC and propidium iodide staining. Specific cell 
death was calculated relative to untreated controls. Three independent experiments. To identify evidence 
for greater than additive effect, a simple linear regression (no intercept model) was used that included drug 
effect for each individual drug and the interaction effect of the combination. SAS software was used in the 
calculations using Proc REG (n = 9 observations for each cell line). Ps are provided. Columns, mean; bars, 
SE. 
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Fig. 4.2 Tipifarnib and Bortezomib are synergistic in cytotoxicity assays. 8226/S (A) and U937 (B) cells 
were treated with Tipifarnib, Bortezomib, or a constant molar ratio (100:1) of the combination for 72 hours. 
Cytotoxicity was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays 
(as described in Materials and Methods). The resulting data was used to generate combination index plots 
(CI) for various dose combinations. The dashed line indicates additive affect (CI = 1). Antagonism (above 
dashed line) and synergism (below dashed line). Tables are included to provide the drug concentrations 
tested. Points, average of quadruplicate values of three independent experiments; bars, SD. 
 
to fibronectin and evaluated for sensitivity to single-agent Tipifarnib and Bortezomib. In 
both lines and with both compounds, a dose-dependent increase in cell death was 
observed in suspension and fibronectin-adhered tumor cells. Importantly, fibronectin 
adherence did not protect tumor cells from Tipifarnib- or Bortezomib-induced apoptosis. 
Furthermore, the Tipifarnib and Bortezomib combination consistently induced cell death 
more efficiently in adhered 8226/S and U937 cells when compared with cells treated in 
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suspension (Fig 4.3 E). Evaluation of three multiple myeloma and five AML patient 
samples also revealed that fibronectin-adhered primary tumor isolates were not protected 
(Fig 4.3E).  These results indicate that Tipifarnib combined with Bortezomib overcomes 
the CAM-DR phenotype. 
 
4.3.3 Reversal of CAM-DR is not related to decreased tumor adherence. 
 
 Because it has been reported that Bortezomib can alter the expression of adhesion 
molecules (Read et al. 1995), we addressed whether the activity of Tipifarnib and 
Bortezomib was related to decreased adherence of tumor cells to fibronectin. 8226/S 
myeloma cells (Fig 4.4 A) and U937 leukemia cells (Fig 4.4 C) were exposed to 
Tipifarnib, Bortezomib, or the combination for 2 hours before adhesion to fibronectin. 
Tumor cell attachment was not prevented in either line, and pre-adhesion drug exposure 
for up to 8 hours revealed no significant decrease in attachment relative to controls (data 
not shown). To verify that Tipifarnib and Bortezomib did not reverse cell adhesion in 
attached tumor cells, 8226/S (Fig 4.4 B) and U937 (Fig 4.4 D) cells were exposed to 
Tipifarnib, Bortezomib, or the combination for 2 hours after being adhered to fibronectin. 
Once again, we detected no reduction in tumor cell adhesion that could explain sensitivity 
to the Tipifarnib and Bortezomib combination. 
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4.3.4 Activation of endoplasmic reticulum stress correlates with reversal of CAM-DR. 
 
It has been reported that the antitumor activity of isoprenoid inhibitors (such as 
FTIs and geranylgeranyl transfeRase inhibitors) may in part be related to inhibition of the 
proteasome proteolytic pathway.  We therefore evaluated proteasome proteolysis in tumor 
cells after Tipifarnib and Bortezomib treatment. We found that Tipifarnib had little to no 
effect on endogenous proteasome activity, and the combination was no more active than 
Bortezomib alone (Fig 4.5 A). Similarly, inhibition of FTase (using HDJ-2 prenylation as 
a surrogate marker) was also not enhanced (Fig 4.5 B). Inhibition of K-Ras farnesylation 
was not observed after treatment with Tipifarnib and/or Bortezomib, consistent with our 
prior report of a Ras-independent mechanism of cell death (Beaupre et al. 2004). These 
results indicate that enhanced activity at the purported targets of Tipifarnib and 
Bortezomib is not responsible for drug synergy; rather, events downstream of the 26S 
proteosome and FTase likely cooperate to activate intrinsic proapoptotic cascades. 
It has been shown that proteasome inhibitors induce apoptosis in myeloma cells 
via triggering of endoplasmic reticulum (ER) stress with subsequent disruption of the 
unfolded protein response (Lee et al. 2003). It has also been observed that proteasome 
inhibitors combined with other compounds that activate ER stress (such as tunicamycin) 
induce cell death in synergy (Lee et al. 2003). Of relevance, we found that Tipifarnib 
activates the ER stress response in multiple myeloma cell lines (Beaupre et al. 2004). 
Based on these observations, we surmised that apoptosis induced by Tipifarnib and 
Bortezomib may be related to activation of the ER stress response. Therefore, 8226/S 
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myeloma cells were exposed to Tipifarnib, Bortezomib, or the combination for 24 hours 
either in suspension culture or after being adhered to fibronectin  (Fig 4.5 C). Activation 
of ER stress was determined by monitoring the expression of GADD153, a well- 
established ER stress marker (Wang et al. 1996). We found that both Tipifarnib and 
Bortezomib increased GADD153 expression under suspension and adhered conditions 
consistent with their ability to activate ER stress–related cascades. Importantly, the 
combination enhanced the ER stress response particularly under fibronectin-adhered 
conditions. These results imply a link between reversal of CAM-DR and activation of the 
ER stress response.  
 
4.3.5 Stroma-adhered tumor cells are sensitive to Tipifarnib and Bortezomib.  
 
Due to the fact that soluble factors may also participate in environment-mediated 
drug resistance, we tested Tipifarnib and Bortezomib in coculture models of the bone 
marrow microenvironment. 8226/S myeloma cells were adhered to HS-5 bone marrow 
stromal cells and then exposed to increasing concentrations of Bortezomib (Fig 4.6 A) or 
Tipifarnib (Fig 4.6 B) for 24 hours. The percentage of live cells decreased in a dose-
dependent manner after treatment with both compounds, and importantly, stroma-adhered 
8226/S cells were nearly as sensitive as suspension cells. Also of significance was the fact 
that high concentrations of Bortezomib and Tipifarnib were not cytotoxic to cocultured 
HS-5 stromal cells (Fig 4.6 A and B). Combined activity was maintained in both stroma-  
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Fig. 4.3. Tipifarnib and Bortezomib induce cell death in fibronectin adhered multiple myeloma 
(MM) and AML cells. 8226/S myeloma cells (A and B) and U937 leukemic cells (C and D) were treated 
with the indicated concentrations of Tipifarnib or Bortezomib for 24 hours either in cell suspension or after 
adhesion to fibronectin. Cell death was determined by flow cytometry after Annexin V/FITC and 
propidium iodide staining. Combined from three independent experiments (A-D). E, 8226/S and U937 cell 
lines along with mononuclear cells from three multiple myeloma and five AML patients were exposed to 5 
µmol/L Tipifarnib and 5 nmol/L Bortezomib for 24 hours either in cell suspension or after adhesion to 
fibronectin. Cell death was determined as in (A-D). In primary isolates, tumor cells were identified by 
staining with anti-CD138 (myeloma cells) or anti-CD33 (leukemic cells) antibodies. For cell lines, five 
(8226/S) and seven (U937) independent experiments were compared using a paired t test with Ps. 
Columns/points, mean; bars, SE. 
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Fig. 4.4 Adhesion to fibronectin is not disrupted by Tipifarnib and Bortezomib. 8226/S myeloma 
cells (A and B) and U937 leukemic cells (C and D) were stained for 30 minutes with the cell tracker 5-
chloromethylfluorescein diacetate (see Materials and Methods). A and C, cells were washed and then 
treated with the indicated concentrations of Tipifarnib, Bortezomib, or the combination for 2 hours (pre-
adhesion exposure). After drug treatment, cells were adhered to fibronectin for an additional 2 hours and 
washed, and fluorescence was analyzed on a fluorescence plate reader. B and D, cells were adhered to 
fibronectin for 2 hours and then exposed to the indicated concentrations of Tipifarnib, Bortezomib, or the 
combination for an additional 2 hours (post-adhesion exposure). Samples were washed, and fluorescence 
was measured as in (C and D). Combined from three independent experiments. Percent adhesion to 
fibronectin is relative to cells treated with control media only. Columns, mean; bars, SE. 
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Fig. 4.5 Reversal of CAM-DR correlates with activation of the ER stress response. A, 8226 
myeloma cells were treated with the indicated concentrations of Tipifarnib and Bortezomib in cell 
suspension for 2 hours. Proteasome activity was measured as described in Materials and Methods. Percent 
proteasome (PS) activity is relative to cells treated with control media. B, 8226/S myeloma cells were 
treated with control media (lane 1), 5 µmol/L Tipifarnib (lane 2), 5 nmol/L Bortezomib (lane 3), or the 
combination (lane 4) for 24 hours in cell suspension. Cell lysates were harvested and analyzed by Western 
blotting using the indicated antibodies. u, unprocessed HDJ-2; p, processed HDJ-2 or K-Ras. C, 8226 
myeloma cells were treated for 12 hours in cell suspension or after adherence to fibronectin as follows: 
suspension, control media (lane 1), 5 µmol/L Tipifarnib (lane 2), 5 nmol/L Bortezomib (lane 3), 10 nmol/L 
Bortezomib (lane 4), 5 µmol/L Tipifarnib and 5 nmol/L Bortezomib (lane 5), 5 µmol/L Tipifarnib and 10 
nmol/L Bortezomib (lane 6); fibronectin, control media (lane 7), 5 µmol/L Tipifarnib (lane 8), 5 nmol/L 
Bortezomib (lane 9), 10 nmol/L Bortezomib (lane 10), 5 µmol/L Tipifarnib and 5 nmol/L Bortezomib (lane 
11), 5 µmol/L Tipifarnib and 10 nmol/L Bortezomib (lane 12). As a control for ER stress, U266 cells were 
either treated with control media (lane 13) or 25 µmol/L tunicamycin (lane 14) for 12 hours. Cell lysates 
were harvested and analyzed by Western blotting using the indicated antibodies. Densitometric evaluation 
of bands. A, combined from three independent experiments. B and C, representative of two independent 
experiments. Columns, mean; bars, SE. 
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adhered and suspension 8226/S cells after treatment with the Tipifarnib and Bortezomib 
combination (Fig 4.6. C). Once again, however, stroma-adhered tumor cells were 
partially protected. A similar trend was observed in U937 leukemia cells (Fig 4.6 D).  
To determine whether HS-5 stromal cells could also protect primary tumor 
isolates, primary multiple myeloma and AML cells were adhered to HS-5 stroma and 
treated with the Tipifarnib and Bortezomib combination (Fig 4.7 A and B). Similar to our 
observations in tumor cell lines, stroma-adhered primary isolates were partially protected 
relative to suspension cells, whereas fibronectin-adhered tumor cells seemed more 
sensitive. Stromal cells derived from a multiple myeloma and two AML patients were 
also able to prevent apoptosis of adhered 8226/S and U937 cells, respectively (Fig 4.7 C-
E).  
 
4.3.6 HS-5 bone marrow stromal cells secrete a protective soluble factor.  
 
Partial resistance provided by bone marrow stromal cells could be explained by 
either CAM-DR or by the participation of protective soluble factors. To address these two 
possibilities, 8226/S myeloma cells (Fig 4.8 A) and U937 leukemia cells (Fig 4.8 B) were 
treated with the combination of Tipifarnib and Bortezomib either in suspension culture 
(suspension), after adhesion to HS-5 stromal cells (coculture), or with separation between 
the two populations using a transwell insert (transwell). As described previously, stroma-
adhered tumor cells were less sensitive to the drug combination when compared with 
cells treated in suspension (36-hour incubation). Interestingly, tumor cells separated from 
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stromal cells using a transwell insert remained protected. These results imply that HS-5 
cells produce a soluble factor(s) that can attenuate the toxicity of Tipifarnib and 
Bortezomib. To determine whether tumor-stroma contact enhanced the production of this 
factor(s), tumor cells were adhered to HS-5 stromal cells and additional tumor cells were 
separated from coculture by a transwell insert (coculture/transwell). The nonadhered 
tumor cells were protected similarly to tumor cells separated by the transwell insert (no 
coculture), suggesting that HS-5 cells constitutively secrete a protective soluble factor(s), 
and its production is not enhanced by tumor-stroma contact. 
 
4.4 Discussion 
 
The emergence of drug resistance continues to be a major obstacle to the 
successful treatment of patients with multiple myeloma and AML. Acquired drug 
resistance is contingent upon the survival of tumor cells during their initial exposure to 
cancer chemotherapy (de novo drug resistance). The interaction between tumor cells and 
components of their microenvironment remains critical during this early phase of 
treatment. Environment-mediated resistance is a result of both physical contact between 
tumor cells and environmental components as well as the exposure of tumor cells to 
soluble factors. Both of these interactions participate in prosurvival processes that allow 
tumor cells to resist chemotherapy and acquire multidrug resistance (Hazlehurst et al. 
2003, Nefedova et al. 2003).  
 
72 
 
 
 
 
 
 
Fig. 4.6 Bone marrow stroma partially protects multiple myeloma and AML cell lines from Tipifarnib- and 
Bortezomib-induced cell death. 8226/S myeloma cells were treated with the indicated concentrations of 
Bortezomib (A), Tipifarnib (B), or the combination (C) for 24 hours. Cells were treated either in suspension 
culture (suspension) or after adhesion to HS-5 stromal cells (adhered). The HS-5 stroma line (stroma) 
expresses GFP in a stable fashion. Myeloma cells were distinguished from stromal cells in coculture by 
using flow cytometry with gating on GFP+ and GFP– populations. D, U937 leukemia cells were treated and 
analyzed as in (C). Cell death was determined by staining with Annexin V/FITC and 7-amino actinomycin-
D as described in Materials and Methods. Percent live cells are relative to tumor cells treated with control 
media only. Combined from three independent experiments (A-D). Columns/points, mean; bars, SE. 
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Fig. 4.7 Stromal cells partially protect primary isolates from the Tipifarnib and Bortezomib combination. 
After obtaining informed consent for bone marrow aspiration, mononuclear cells from a multiple myeloma 
(A) and an AML (B) patient were isolated by Ficoll-Hypaque gradient purification. Cells were treated with 
the combination of 5 µmol/L Tipifarnib and 5 nmol/L Bortezomib for 36 hours either in suspension or after 
adhesion to fibronectin or HS-5 bone marrow stromal cells. Cell death was determined by flow cytometry 
after Annexin V/FITC and 7-amino actinomycin-D staining. Tumor cells were identified in coculture by 
staining with anti-CD138 (myeloma cells) or anti-CD33 (leukemic cells) antibodies. 8226/S myeloma cells 
(C) and U937 leukemic cells (D and E) were adhered to HS-5 stroma and bone marrow stromal cells 
derived from a patient with multiple myeloma (C) and AML (D and E), respectively. Tumor cells were 
exposed to 5 µmol/L Tipifarnib and 5 nmol/L Bortezomib for 36 hours, and cell death was determined as 
described above. Cell death in adhered samples was compared with tumor cell lines treated in suspension 
culture. Columns, mean; bars, SE. 
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Fig. 4.8 HS-5 stromal cells secrete a soluble factor(s) that protects multiple myeloma and AML cell lines. 
8226/S myeloma (A) and U937 leukemia cells (B) were treated with 5 µmol/L Tipifarnib and 5 nmol/L 
Bortezomib for 36 hours. Tumor cells were maintained as follows: in suspension culture (suspension), 
adhered to HS-5 GFP stromal cells (coculture), separated from HS-5 GFP stromal cells by a transwell insert 
(transwell), or adhered to HS-5 GFP stromal cells with additional tumor cells separated by a transwell 
insert (coculture/transwell). In the latter sample, nonadhered tumor cells were harvested for evaluation. Cell 
death was determined by flow cytometry after staining with Annexin V/FITC and 7-amino actinomycin-D. 
In coculture, death of myeloma and leukemia cells was determined by gating on GFP– cells. Combined 
from three independent experiments (A and B). Individual conditions were compared using a paired t test 
with Ps. Columns, mean; bars, SE. 
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Novel agents or drug combinations that overcome de novo drug resistance are eagerly 
sought. Tipifarnib is a FTI that has clinical activity in multiple myeloma and AML 
(Alsina et al. 2004, Karp et al. 2001). Interestingly, Tipifarnib accumulates in bone 
marrow (Karp et al. 2001), a desirable property in hematopoietic malignancies that are 
dependent on the bone marrow microenvironment. We observed that as a single-agent 
Tipifarnib can overcome the CAM-DR phenotype in multiple myeloma and AML cell 
lines (Fig 4.3 A and C) and primary isolates (data not shown). It had previously been 
reported that Bortezomib shares similar activity in fibronectin-adhered (Mitsiades et al. 
2006) and stroma-adhered (Hideshima et al. 2001) MM1s myeloma cells, and consistent 
with this, we found that Bortezomib efficiently induced cell death in stroma-adhered 
8226/S myeloma cells (Fig 4.6 A). Because Bortezomib has been shown to sensitize 
fibronectin-adhered myeloma cells to chemotherapy-mediated apoptosis (Mitsiades et al. 
2003), we set out to discern whether low doses of Bortezomib (5 nmol/L) could enhance 
the activity of Tipifarnib in microenvironment models of multiple myeloma and AML.  
Our data reveal that this combination has activity not only in multiple myeloma 
and AML cells maintained in suspension culture (Fig 4.1) but also in tumor cells adhered 
to the extracellular matrix component fibronectin (Fig 4.3), indicating that Tipifarnib 
combined with Bortezomib effectively overcomes CAM-DR. It has been previously 
reported that Bortezomib decreases the adhesion of myeloma cells to bone marrow 
stromal cells (Hideshima et al. 2001). Conversely, Tipifarnib did not reduce the adhesion 
of AML blasts to either primary bone marrow stroma or human umbilical endothelial 
cells (Liesveld et al. 2003). In our models, Tipifarnib, Bortezomib, nor the combination 
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decreased tumor cell adhesion to fibronectin implying that cell death was not associated 
with the loss of tumor-microenvironment contact (Fig 4.4). Stroma-adhered tumor cells 
were also sensitive to the combination, although they were partially protected relative to 
cells maintained in suspension culture (Fig 4.6 and 4.7). The fact that Tipifarnib and 
Bortezomib were particularly active in fibronectin-adhered tumor cells leads us to 
consider soluble factors as a possible source of stroma-mediated resistance. In 
experiments where tumor cells were physically separated from stromal cells using a 
transwell insert, protection persisted confirming that a soluble factor(s) could partially 
suppress the activity of the drug combination (Fig 4.8).  
Several key cytokines serve as autocrine and paracrine growth factors for multiple 
myeloma and AML cells. IL-6 is known to be a major growth and survival factor in 
multiple myeloma (Hallek et al. 1998). IL-6 is secreted by HS-5 bone marrow stromal 
cells (Roecklein et al. 1995) and protects multiple myeloma cells from dexamethasone-
mediated apoptosis (Chauhan et al. 2000). Of importance, it has been reported that IL-6 is 
incapable of protecting myeloma cells from Bortezomib-induced cell death (Hideshima et 
al. 2001). It therefore remains possible that other cytokines and/or growth factors are 
involved. HS-5 stromal cells also secrete IL-1ß that can contribute to autocrine and 
paracrine growth loops in multiple myeloma (Kawano et al. 1989, Nagata et al. 1991) and 
AML (Sakai et al. 1987, Cozzolino et al. 1989). However, we previously reported that an 
FTI inhibits the expression of IL-1ß in leukemic cell lines (Beupre et al. 1999), implying 
that IL-1ß is not the protective cytokine in our models. Vascular endothelial growth factor 
has also been shown to promote the growth of multiple myeloma (Podar et al. 2001) and 
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AML cells (List et al. 2004), and its mRNA is expressed in HS-5 stromal cells (Roecklein 
et al. 1995). It remains to be seen whether any of the abovementioned cytokines are 
relevant to the observed stromal-mediated resistance, but experiments are under way to 
define the cytokine(s) and/or growth factor(s) involved. Our findings will have clinical 
relevance for antagonists to all three of these factors, as well as other soluble proteins are 
being clinically tested.  
With respect to the mechanism of action of this drug combination, as single 
agents, both Tipifarnib and Bortezomib have been shown to induce ER stress–related 
apoptosis (Beaupre et al. 2004, Lee et al. 2003, Landowski et al. 2005, Fribley et al. 
2004). We found that the combination enhanced activation of the ER stress marker 
GADD153 (Fig 4.5 C), and this correlated with apoptosis and reversal of CAM-DR. We 
have previously observed that Tipifarnib increases the expression and activity of Bax 
(Beaupre et al. 2004) and Bim in myeloma cell lines. Interestingly, it has been reported 
that the expression of Bax and Bim can be regulated via a proteasome-mediated pathway 
(Luciano et al. 2003, Li et al. 2000). It therefore remains possible that Tipifarnib and 
Bortezomib cooperate to enhance the activity of these proapoptotic proteins. Bax and Bim 
are known to target the ER, leading to ER calcium release (Scorrano et al. 2003), 
activation of caspase-12 (Morishima et al. 2003, and apoptosis in a mitochondria-
independent fashion (Morishima et al. 2002). Mitochondrial dysfunction also occurs after 
Tipifarnib treatment (Beaupre et al. 2004) and is likely the result of localization of Bax 
and Bim to mitochondria. It remains possible, however, that intracytoplasmic calcium 
participates in mitochondrial membrane depolarization by opening of the mitochondrial 
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permeability transition pore (Landowshi et al. 2005, Rizzuot et al. 2003). Importantly, 
Tipifarnib and Bortezomib are active when tumor cells are adhered to fibronectin. Bim 
expression is known to decrease in adhered myeloma cells (Hazlehurst et al. 2003), and it 
remains possible that the combination reverses this effect. Current investigations are 
determining the role of Bax and Bim in reversal of the CAM-DR phenotype. Delineation 
of the ER stress–related mechanisms responsible for Tipifarnib and Bortezomib 
combined activity may ultimately lead to treatment strategies that specifically target 
environment-mediated drug resistance.  
In conclusion, in this study, we provide the preclinical rationale for clinical trials 
testing Tipifarnib and Bortezomib in patients with multiple myeloma and AML. Future 
trials may also include a cytokine and/or growth factor neutralization strategy once 
protective soluble factors are identified. In theory, such a regimen would eradicate tumor 
cells protected by the microenvironment compartment, leaving sensitive tumor cell 
populations for standard or high-dose chemotherapy. 
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Chapter 5 
Summary and Major Conclusions 
 
5.1 Identification and characterization of the R115777 resistant cell line 
 
The farnesyl transferase inhibitor R115777 has been found to have clinical 
activity in diverse hematopoietic tumors. Clinical efficacy, however, does not correlate 
with Ras mutation status or inhibition of farnesyl transferase. To further elucidate the 
mechanisms by which R115777 induces apoptosis and to investigate drug resistance, we 
identified and characterized a R115777-resistant human myeloma cell line. 8226/R5 cells 
were found to be at least 50 times more resistant to R115777 compared with the parent 
cell line 8226/S. K-Ras remained prenylated in both resistant and sensitive cells after 
R115777 treatment; however, HDJ-2 farnesylation was inhibited in both lines, implying 
that farnesyl transfeRase (the drug target) has not been mutated. Whereas many 8226 
lines that acquire drug resistance have elevated expression of P-glycoprotein, we found 
that P-glycoprotein expression is not increased in the 8226/R5 line and intracellular 
accumulation of R115777 was not reduced. In fact, 8226/R5 cells were insensitive to a 
diverse group of antitumor agents including PS-341, and multidrug resistance did not 
correlate with the expression of heat shock proteins. Comparison of gene expression 
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profiles between resistant and sensitive cells revealed expression changes in several genes 
involved in myeloma survival and drug resistance. Identification of molecules associated 
with R115777 and PS-341 resistance is clinically relevant because both compounds are 
being tested in solid tumors and hematopoietic malignancies. 
 
5.2 The role of the Akt survival pathway in R115777 induced apoptosis and resistance 
 
 It has been well described that R115777 induces apoptosis in a RAS-independent 
manner.  In this study I have implicated Akt as a possible culprit in the cytotxic resistance 
to R115777.  I have demonstrated that Tipifarnib induces apoptosis in myeloma cell lines 
when AKT in not endogenously active.  As such, we were able to correlate levels of pAkt 
expression to drug resistance in multiple myeloma in cell lines.  In MM primary isolates, 
AKT has been found to be predominately activated and localized to the nucleus. 
However, no direct correlation between Akt localization and drug resistance has yet been 
characterized until now.  Here we have demonstrated a correlation between nuclear 
localization of pAkt and drug resistance in MM cells. Utalizing a SCID-hu model of 
myeloma we were successful in exhibiting the in vivo cytoxicity of myeloma cells from 
R115777. 
 
5.3 Combination treatment using R15777 and PS-341  
 It has been established in preclinical models of multiple myeloma and acute 
myeloid leukemia (AML) that the bone marrow microenvironment provides protection 
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from chemotherapy- and death receptor–mediated apoptosis. This form of resistance, 
termed de novo drug resistance, occurs independent of chronic exposure to cancer-related 
therapies and likely promotes the development of multidrug resistance. Consequently, it 
is of major interest to identify compounds or drug combinations that can overcome 
environment-mediated resistance. In this study, we investigated the activity of Tipifarnib 
(Zarnestra, formerly R115777) combined with Bortezomib (Velcade, formerly PS-341) in 
microenvironment models of multiple myeloma and AML. The combination proved to be 
synergistic in multiple myeloma and AML cell lines treated in suspension culture. Even 
in tumor cells relatively resistant to Tipifarnib, combined activity was maintained. 
Tipifarnib and Bortezomib were also effective when multiple myeloma and AML cells 
were adhered to fibronectin, providing evidence that the combination overcomes cell 
adhesion–mediated drug resistance (CAM-DR). Of importance, activation of the 
endoplasmic reticulum stress response was enhanced and correlated with apoptosis and 
reversal of CAM-DR. Multiple myeloma and AML cells cocultured with bone marrow 
stromal cells also remained sensitive, although stromal-adhered tumor cells were partially 
protected (relative to cells in suspension or fibronectin adhered). Evaluation of the 
combination using a transwell apparatus revealed that stromal cells produce a protective 
soluble factor. Investigations are under way to identify the cytokines and/or growth 
factors involved. In summary, our study provides the preclinical rationale for trials testing 
the Tipifarnib and Bortezomib combination in patients with multiple myeloma and AML. 
 
 
82 
 
 
 
 
 
Literature Cited 
 
Adini I, Rabinovitz I, Sun JF, Prendergast GC, Benjamin LE. RhoB controls Akt 
trafficking and stage-specific survival of endothelial cells during vascular development. 
Genes & development. 2003 Nov 1;17(21):2721-32. 
 
Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-
Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated 
apoptosis. Clin Cancer Res 2003;9:316–26.  
 
Alkan S, Izban KF. Immunohistochemical localization of phosphorylated AKT in 
multiple myeloma. Blood. 2002 Mar 15;99(6):2278-9. 
 
Alsina M, Fonseca R, Wilson EF, et al. The farnesyltransferase inhibitor Zarnestra is well 
tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic/tumor 
survival pathways in patients with advanced multiple myeloma. Blood 2004;103:3271–7.  
 
Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek 
G, Fenton RG. Neurotoxicity of Bortezomib therapy in multiple myeloma: a single-center 
experience and review of the literature. Cancer. Sep 1;110(5):1042-9 (2007) 
 
Bauduer F, Troussard X, Delmer A. Prognostic factors in multiple myeloma. Review of 
the literature. Bull Cancer 1993;80:1035–42.  
 
Beaupre DM, Cepero E, Obeng EA, Boise LH, Lichtenheld MG. R115777 induces Ras-
independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol Cancer 
Ther 2004;3:179–86.  
83 
 
 
Beaupre DM, McCafferty-Grad J, Bahlis NJ, Boise LH, Lichtenheld MG. Farnesyl 
transferase inhibitors enhance death receptor signals and induce apoptosis in multiple 
myeloma cells. Leuk Lymphoma 2003;44:2123–34.  
 
Beaupre DM, Talpaz M, Marini FC, III, et al. Autocrine interleukin-1ß production in 
leukemia: evidence for the involvement of mutated RAS. Cancer Res 1999;59:2971–80.  
 
Bergsagel D. The incidence and epidemiology of plasma cell neoplasms. Stem cells 
(Dayton, Ohio). 1995 Aug;13 Suppl 2:1-9. 
 
Bezieau S, Devilder MC, Avet-Loiseau H, et al. High incidence of N- and K-Ras 
activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. 
Hum Mutat 2001;18:212–24. 
 
Bharti AC, Shishodia S, Reuben JM, et al. Nuclear factor- B and STAT3 are 
constitutively active in CD138+ cells derived from multiple myeloma patients, and 
suppression of these transcription factors leads to apoptosis. Blood 2004;103:3175–84.  
 
Bolick SC, Landowski TH, Boulware D, et al. The farnesyl transferase inhibitor, FTI-
277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. 
Leukemia 2003;17:451–7.  
 
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell 
survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999 
Mar 19;96(6):857-68. 
 
Brunner TB, Hahn SM, Gupta AK, Muschel RJ, Mckenna WG, Bernhard EJ. 
FarnesyltransfeRase inhibitors: An overview of the results of preclinical and clinical 
investigations. Cancer Research. 2003. 64, 565605668 
84 
 
 
Buzzeo R, Enkemann S, Nimmanapalli R, Alsina M, Lichtenheld MG, Dalton WS, et al. 
Characterization of a R115777-resistant human multiple myeloma cell line with cross-
resistance to PS-341. Clin Cancer Res. 2005 Aug 15;11(16):6057-64. 
 
Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002 May 
31;296(5573):1655-7. 
 
Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 
signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 
1999;10:105–15.  
 
Chantry D, Vojtek A, Kashishian A, et al. p110 , a novel phosphatidylinositol 3-kinase 
catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J 
Biol Chem 1997;272:19236–41.  
 
Chauhan D, Li G, Auclair D, et al. 2-Methoxyestardiol and bortezomib/proteasome-
inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating 
Heat Shock Protein-27. Apoptosis 2004;9:149–55.  
 
Chauhan D, Li G, Shringarpure R, et al. Blockade of Hsp27 overcomes 
Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 
2003;63:6174–7.  
 
Chauhan D, Pandey P, Hideshima T, et al. SHP2 mediates the protective effect of 
interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol 
Chem 2000;275:27845–50.  
 
Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined 
effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27–55.  
85 
 
 
Corradini P, Ladetto M, Inghirami G, et al. N- and K-ras oncogenes in plasma cell 
dyscrasias. Leuk Lymphoma 1994;15:17–20.  
 
Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor 
R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 
2003;101:1692–7.  
 
Cortes JE, Kurzrock R, Kantarjian HM. Farnesyltransferase inhibitors: novel compounds 
in development for the treatment of myeloid malignancies. Seminars in hematology. 2002 
Jul;39(3 Suppl 2):26-30. 
 
Cox AD. Farnesyltransferase inhibitors: potential role in the treatment of cancer. Drugs. 
2001;61(6):723-32. 
 
Cozzolino F, Rubartelli A, Aldinucci D, et al. Interleukin 1 as an autocrine growth factor 
for acute myeloid leukemia cells. Proc Natl Acad Sci U S A 1989;86:2369–73.  
 
Cunningham D, de Gramount A, Scheithauer W, Smakal M, Humblet Y, Kurteva G, 
Ivenson T, Andre T, Dostalova J, Illes A, Jia X, Palmer P. Randomized double-blind 
placebo controlled trial of the farnesyltransfeRase inhibitor R115777 (Zarnestra) in 
advanced refractory colorectal cancer (PC). Proc. Am. Soc. Clin. Oncol. 21:502, 2002 
 
Dai Y, Rahmani M, Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis 
induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and 
NF- B-dependent process. Oncogene 2003;22:7108–22.  
 
 
 
86 
 
Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell 
line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proceedings of 
the National Academy of Sciences of the United States of America. 1988 
Dec;85(23):9312-6. 
 
Dalton WS, Durie BG, Alberts DS, et al. Characterization of a new drug-resistant human 
myeloma cell line that expresses P-glycoprotein. Cancer Res 1986;46:5125–30.  
 
Dalton WS. Mechanisms of drug resistance in hematologic malignancies. Seminars in 
hematology. 1997 Oct;34(4 Suppl 5):3-8. 
 
Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated 
drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human 
myeloma cell lines. Blood 1999;93:1658–67.  
 
Dominik D. Alexander, Pamela J. Mink, Hans-Olov Adami, Phillip Cole, Jack Mandel, 
Martin M. Oken and Dimitrios Trichopoulos. Multiple myeloma: A review of the 
epidemiologic literature. Int. J. Cancer: 120, 40-61 (2007) 
 
Du W, Liu A, Prendergast GC. Activation of the PI3'K-AKT pathway masks the 
proapoptotic effects of farnesyltransferase inhibitors. Cancer Res. 1999 Sep 
1;59(17):4208-12. 
 
DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, et al. Transformation-
selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. 
Oncogene. 2003 Jun 5;22(23):3578-88. 
 
End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the 
selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 
2001;61:131–7.  
87 
 
 
Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, et al. The protein 
kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated 
phosphatidylinositol 3-kinase. Cell. 1995 Jun 2;81(5):727-36. 
 
Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through 
induction of endoplasmic reticulum stress-reactive oxygen species in head and neck 
squamous cell carcinoma cells. Mol Cell Biol 2004;24:9695–704.  
 
Gelb MH, Tamanoi F, Yokoyama K, et al. The inhibition of protein prenyltransferases by 
oxygenated metabolites of limonene and perillyl alcohol. Cancer Lett 1995;91:169–75.  
 
Ghafoor A, Jemal A, Cokkinides V, Cardinez C, Murray T, Samuels A, et al. Cancer 
statistics for African Americans. CA: a cancer journal for clinicians. 2002 Nov-
Dec;52(6):326-41. 
 
Grad JM, Zeng XR, Boise LH. Regulation of Bcl-xL: a little bit of this and a little bit of 
STAT. Curr Opin Oncol 2000;12:543–9.  
 
Hahn SM, Bernhard E, McKenna WG. Farnesyltransferase inhibitors. Seminars in 
oncology. 2001 Oct;28(5 Suppl 16):86-93. 
 
Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a 
multistep transformation process. Blood. 1998 Jan 1;91(1):3-21. 
 
Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated 
but only some are palmitoylated. Cell. 1989 Jun 30;57(7):1167-77. 
 
88 
 
Hanks SK, Calab MB, Harper MC, Patel SK: Focal adhesion protein-tyrosine kinase 
phosphorylated in response to cell spreading on fibronectin. Proc Natl Acad Sci 89: 8487-
8491, 1992 
 
Hazlehurst LA, Enkemann SA, Beam CA, et al. Genotypic and phenotypic comparisons 
of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line 
model. Cancer Res 2003;63:7900–6.  
 
Hazlehurst LA, Landowski TH, Dalton WS. Role of the tumor microenvironment in 
mediating de novo resistance to drugs and physiological mediators of cell death. 
Oncogene 2003;22:7396–402.  
 
Hideshima T, Nakamura N, Chauhan D, et al. Biologic sequelae of interleukin-6 induced 
PI3-K/Akt signaling in multiple myeloma. Oncogene 2001;20:5991–6000.  
 
Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits 
growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma 
cells. Cancer Res 2001;61:3071–6.  
 
Hiles ID, Otsu M, Volinia S, et al. Phosphatidylinositol 3-kinase: structure and 
expression of the 110 kd catalytic subunit. Cell 1992;70:419–29.  
 
Hsu JH, Shi Y, Hu L, et al. Role of the AKT kinase in expansion of multiple myeloma 
clones: effects on cytokine-dependent proliferative and survival responses. Oncogene 
2002;21:1391–400.  
 
Hu W, Wu W, Verschraegen CF, et al. Proteomic identification of heat shock protein 70 
as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor. 
Proteomics 2003;3:1904–11.  
 
89 
 
Huang HM, Lin YL, Chen CH, Chang TW. Simultaneous activation of JAK1 and JAK2 
confers IL-3 independent growth on Ba/F3 pro-B cells. Journal of cellular biochemistry. 
2005 Oct 1;96(2):361-75. 
 
Jiang K, Coppola D, Crespo NC, et al. The phosphoinositide 3-OH kinase/AKT2 
pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell 
Biol 2000;20:139–48.  
 
Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment 
of multiple myeloma progressing on prior therapy. Oncologist 2003;8:508–13.  
 
Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the 
farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute 
leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001;97:3361–9.  
 
Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ. Isoprenoid addition to Ras 
protein is the critical modification for its membrane association and transforming activity. 
Proceedings of the National Academy of Sciences of the United States of America. 1992 
Jul 15;89(14):6403-7. 
 
Kawano M, Tanaka H, Ishikawa H, et al. Interleukin-1 accelerates autocrine growth of 
myeloma cells through interleukin-6 in human myeloma. Blood 1989;73:2145–8.  
 
Keating A. Chronic myeloid leukemia: current therapies and the potential role of 
farnesyltransferase inhibitors. Semin Hematol 2002;39:11–7.  
 
Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, et al. Preclinical 
antitumor activity and pharmacodynamic studies with the farnesyl protein transferase 
inhibitor R115777 in human breast cancer. Clin Cancer Res. 2001 Nov;7(11):3544-50. 
 
90 
 
King WG, Maytaliano CTO, Tsichilis PN, Brugge JS, Phosphatidylinosital 3-kinase is 
required for integrin-stimulated AKT and RAF-1/mitogen-activated protein kinase 
pathway activation. Mol Cell Biol 17:4406-4418, 1997 
 
Kurzrock R, Cortes J, Kantarjian H. Clinical development of farnesyltransferase 
inhibitors in leukemias and myelodysplastic syndrome. Semin Hematol 2002;39:20–4.  
 
Kyle R. Rajkumar V. Multiple Myeloma. The New England Journal of Medicine. 
Volume 351:1860-1873 (2004)  
 
Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT. Mitochondrial-mediated 
disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) 
cytotoxicity in myeloma cell lines. Cancer Res 2005;65:3828–36.  
 
Lavie Y, Liscovitch M. Changes in lipid and protein constituents of rafts and caveolae in 
multidrug resistant cancer cells and their functional consequences. Glycoconj J 
2000;17:253–9.  
 
Le Gouill S, Pellat-Deceunynck C, Harousseau JL, et al. Farnesyl transferase inhibitor 
R115777 induces apoptosis of human myeloma cells. Leukemia 2002;16:1664–7.  
 
Lebowitz PF, Eng-Wong J, Widemann BC, Balis FM, Jayaprakash N, Chow C, et al. A 
phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and 
tamoxifen in metastatic breast cancer. Clin Cancer Res. 2005 Feb 1;11(3):1247-52. 
 
LeCouter J, Zlot C, Tejada M, Peale F, Ferrara N. Bv8 and endocrine gland-derived 
vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell 
mobilization. Proc Natl Acad Sci U S A 2004;101:16813–8. 
 
91 
 
Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the 
unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 2003;100:9946–
51.  
 
Lee JW, Juliano RL: Alpha 5 beta 1 integrin protects intestinal epithelial cells from 
apoptosis through a phosphatidylinositol 3-kinase and protein kinase B-dependent 
pathway. Mol Biol Cell 11: 1973-1987, 2000 
 
Lerner EC, Qian Y, Blaskovich MA, et al. Ras CAAX peptidomimetic FTI-277 
selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of 
inactive Ras-Raf complexes. J Biol Chem 1995;270:26802–6.  
 
Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: 
involvement in tumor survival and progression. Proc Natl Acad Sci U S A 2000;97:3850–
5.  
 
Liesveld JL, Lancet JE, Rosell KE, et al. Effects of the farnesyl transferase inhibitor 
R115777 on normal and leukemic hematopoiesis. Leukemia 2003;17:1806–12.  
 
Lin TH, Aplin AE, Shen Y, Chen Q, Schaller M, Romer L, Aukhil I, Juliano RL: 
Integrin-mediated activation of MAP kinase is independent of FAK: Evidence for dual 
integrin signaling pathways in fibroblasts. J Cell Biol 136: 1385-1395, 1997 
 
List AF, Glinsmann-Gibson B, Stadheim C, Meuillet EJ, Bellamy W, Powis G. Vascular 
endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-
kinase-dependent clonogenic response in acute myeloid leukemia cells. Exp Hematol 
2004;32:526–35.  
 
92 
 
Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, et al. Activating mutations of 
N- and K-ras in multiple myeloma show different clinical associations: analysis of the 
Eastern Cooperative Oncology Group Phase III Trial. Blood. 1996 Oct 1;88(7):2699-706. 
 
Liu WM, Mei R, Di X, et al. Analysis of high density expression microarrays with 
signed-rank call algorithms. Bioinformatics 2002;18:1593–9.  
 
Luciano F, Jacquel A, Colosetti P, et al. Phosphorylation of Bim-EL by Erk1/2 on serine 
69 promotes its degradation via the proteasome pathway and regulates its proapoptotic 
function. Oncogene 2003;22:6785–93.  
 
Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances 
sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 
2003;9:1136–44.  
 
Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin AS, Jr., Mayo MW. Akt 
suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit 
of NF-kappaB. Molecular and cellular biology. 2000 Mar;20(5):1626-38. 
 
Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemic-cell VLA-4 and 
stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous 
leukemia. Nat Med 2003;9:1158–65.  
 
Meng F, Lowell CA: A beta 1 integrin signaling pathway involving Src-family kinases, 
Cbl and Pi-3 kinase is required for macrophage spreading and migration. EMBO J 17: 
4391-4403, 1998 
 
Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 
potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic 
agents: therapeutic applications. Blood 2003;101:2377–80.  
93 
 
 
Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y. An endoplasmic 
reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent 
activation of caspase-9 by caspase-12. J Biol Chem 2002;277:34287–94.  
 
Morishima N, Nakanishi K, Tsuchiya K, Shibata T, Seiwa E. Translocation of Bim to the 
endoplasmic reticulum (ER) mediates ER stress signaling for activation of caspase-12 
during ER stress-induced apoptosis. J Biol Chem 2004;279:50375–81. 
 
Nagata K, Tanaka Y, Oda S, Yamashita U, Eto S. Interleukin 1 autocrine growth system 
in human multiple myeloma. Jpn J Clin Oncol 1991;21:22–9.  
 
Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors 
and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct 
mechanisms. Leukemia 2003;17:1175–82.  
 
Neri A, Murphy JP, Cro L, Ferrero D, Tarella C, Baldini L, et al. Ras oncogene mutation 
in multiple myeloma. The Journal of experimental medicine. 1989 Nov 1;170(5):1715-
25. 
 
Ochiai N, Uchida R, Fuchida S, Okano A, Okamoto M, Ashihara E, et al. Effect of 
farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells 
in vitro. Blood. 2003 Nov 1;102(9):3349-53. 
 
Onishi M, Nosaka T, Misawa K, Mui AL, Gorman D, McMahon M, et al. Identification 
and characterization of a constitutively active STAT5 mutant that promotes cell 
proliferation. Molecular and cellular biology. 1998 Jul;18(7):3871-9. 
 
94 
 
Otsu M, Hiles I, Gout I, et al. Characterization of two 85 kd proteins that associate with 
receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell 
1991;65:91–104.  
 
Palumbo, Gay, Bringhen, Falcone, Pescosta, Callea, Caravita, Morabito, Magarotto, 
Ruggeri, Avonto, Musto, Cascavilla, Bruno and Boccadoro. Bortezomib, doxorubicin and 
dexamethasone in advanced multiple myeloma. Annals of Oncology. 19(6):1160-1165. 
(2008) 
 
Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human 
multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase 
inhibitors. Clin Cancer Res. 2004 Jun 1;10(11):3839-52. 
 
Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling 
cascades mediating multiple myeloma cell growth and migration. Blood 2001;98:428–35.  
 
Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T. The 
proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion 
molecule expression. Immunity 1995;2:493–506.  
 
Richardson P, Anderson K. Immunomodulatory analogs of thalidomide: an emerging 
new therapy in myeloma. J Clin Oncol. 2004 Aug 15;22(16):3212-4. 
 
Rizzuto R, Pinton P, Ferrari D, et al. Calcium and apoptosis: facts and hypotheses. 
Oncogene 2003;22:8619–27.  
 
Roecklein BA, Torok-Storb B. Functionally distinct human marrow stromal cell lines 
immortalized by transduction with the human papilloma virus E6/E7 genes. Blood 
1995;85:997–1005.  
 
95 
 
Sakai K, Hattori T, Matsuoka M, et al. Autocrine stimulation of interleukin 1 ß in acute 
myelogenous leukemia cells. J Exp Med 1987;166:1597–602.  
 
Santucci R, Mackley PA, Sebti S, Alsina M. Farnesyltransferase inhibitors and their role 
in the treatment of multiple myeloma. Cancer Control. 2003 Sep-Oct;10(5):384-7. 
 
Scorrano L, Oakes SA, Opferman JT, et al. BAX and BAK regulation of endoplasmic 
reticulum Ca2+: a control point for apoptosis. Science 2003;300:135–9.  
 
Sebti S, Hamilton AD. Inhibitors of prenyl transferases. Current opinion in oncology. 
1997 Nov;9(6):557-61. 
 
Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors 
and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. 
Oncogene 2000;19:6584–93.  
 
Shain KH, Dalton WS. Cell adhesion is a key determinant in de novo multidrug 
resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther 
2001;1:69–78.  
 
Smith V, Rowlands MG, Barrie E, et al. Establishment and characterization of acquired 
resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer 
cell line. Clin Cancer Res 2002;8:2002–9.  
 
Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and 
geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras 
prenylation but each alone is sufficient to suppress human tumor growth in nude mouse 
xenografts. Oncogene. 1998 Mar;16(11):1467-73. 
 
 
96 
 
Takada Y, Khuri FR, Aggarwal BB. Protein farnesyltransferase inhibitor (SCH 66336) 
abolishes NF-kappaB activation induced by various carcinogens and inflammatory 
stimuli leading to suppression of NF-kappaB-regulated gene expression and up-
regulation of apoptosis. The Journal of biological chemistry. 2004 Jun 18;279(25):26287-
99. 
 
Tamanoi F, Gau CL, Jiang C, Edamatsu H, Kato-Stankiewicz J. Protein farnesylation in 
mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell Mol Life 
Sci. 2001 Oct;58(11):1636-49. 
 
Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase 
pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and 
proliferative responses. Cancer research. 2000 Dec 1;60(23):6763-70. 
 
Tu Y, Renner S, Xu F, et al. BCL-X expression in multiple myeloma: possible indicator 
of chemoresistance. Cancer Res 1998;58:256–62.  
 
Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA, et al. The 
development of a model for the homing of multiple myeloma cells to human bone 
marrow. Blood. 1997 Jul 15;90(2):754-65. 
 
Van Cutsem E, KaRasek P, Oettle H, Vervenne W, Szawlowski A, Schoffskiu P, Post S, 
Neumann H, Safran H, Humblet Y, van de Velde H, Ma Y, Von Hoff D. Phase III trial 
comparing gemcitabine + R115777 (Zarnestra versus gemcitabine + Placebo in advanced 
pancreatic cancer (PC). Proc. Am. Soc. Clin. Oncol. 2002. 21:517 
 
Van der Velde-Zimmermann D, Verdaasdonk MAM, Joling P. Fibronectin distribution in 
human bone marrow stroma: Matrix assembly and tumor cell adhesion via alpha-5 beta-1 
integrin. Exp Cell Research. 1996 Oct 3400-3405 
 
97 
 
Van Gelder RN, von Zastrow ME, Yool A, et al. Amplified RNA synthesized from 
limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A 1990;87:1663–7.  
 
Vanhaesebroeck B, Welham MJ, Kotani K, et al. P110 , a novel phosphoinositide 3-
kinase in leukocytes. Proc Natl Acad Sci U S A 1997;94:4330–5.  
 
Wang XZ, Lawson B, Brewer JW, et al. Signals from the stressed endoplasmic reticulum 
induce C/EBP-homologous protein (CHOP/GADD153). Mol Cell Biol 1996;16:4273–80.  
 
Warrington JA, Nair A, Mahadevappa M, et al. Comparison of human adult and fetal 
expression and identification of 535 housekeeping/maintenance genes. Physiol Genomics 
2000;2:143–7.  
 
Weber D. Thalidomide and its derivatives: new promise for multiple myeloma. Cancer 
Control. 2003 Sep-Oct;10(5):375-83. 
 
Weber DM. Newly diagnosed multiple myeloma. Current treatment options in oncology. 
2002 Jun;3(3):235-45. 
 
Willumsen BM, Christensen A, Hubbert NL, Papageorge AG, Lowy DR. The p21 ras C-
terminus is required for transformation and membrane association. Nature. 1984 Aug 16-
22;310(5978):583-6. 
 
Yanamandra N, Colaco NM, Parquet NA, Buzzeo RW, Boulware D, Wright G, et al. 
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug 
resistance in multiple myeloma and acute myeloid leukemia.  
 
 
 
98 
 
Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, et al. 
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel 
to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma 
cells. Blood. 2005 Jun 15;105(12):4759-66. 
 
 
 
 
 
 
